{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T18:15:59Z","timestamp":1791569759957,"version":"4.3.4"},"reference-count":217,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,2,24]]},"DOI":"10.7759\/cureus.79569","type":"journal-article","created":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T17:09:36Z","timestamp":1740416976000},"source":"Crossref","is-referenced-by-count":7,"title":["Neurological Manifestations of Systemic Lupus Erythematosus: A Comprehensive Review"],"prefix":"10.7759","author":[{"given":"Maleesha","family":"Jayasinghe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatemeh","family":"Rashidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed Farid","family":"Gadelmawla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamir","family":"Pitton Rissardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masoumeh","family":"Rashidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher C","family":"Elendu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Leticia","family":"Fornari Caprara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim","family":"Khalil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalil I","family":"Hmedat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Atef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hania","family":"Moharam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omesh","family":"Prathiraja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1002\/art.40396","article-title":"Abnormal B cell development in systemic lupus erythematosus: what the genetics tell us","volume":"70","author":"Karrar S","year":"2018","unstructured":"Karrar S, Cunninghame Graham DS. Abnormal B cell development in systemic lupus erythematosus: what the genetics tell us. Arthritis Rheumatol. 2018, 70:496-507. 10.1002\/art.40396","journal-title":"Arthritis Rheumatol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00541","article-title":"Autoantibodies associated with connective tissue diseases: what meaning for clinicians?","volume":"9","author":"Didier K","year":"2018","unstructured":"Didier K, Bolko L, Giusti D, Toquet S, Robbins A, Antonicelli F, Servettaz A. Autoantibodies associated with connective tissue diseases: what meaning for clinicians?. Front Immunol. 2018, 9:541. 10.3389\/fimmu.2018.00541","journal-title":"Front Immunol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/2385386","article-title":"Characterisation of patients with systemic lupus erythematosus in Malta: a population based cohort cross-sectional study","volume":"2018","author":"Magro R","year":"2018","unstructured":"Magro R, Borg AA. Characterisation of patients with systemic lupus erythematosus in Malta: a population based cohort cross-sectional study. Biomed Res Int. 2018, 2018:2385386. 10.1155\/2018\/2385386","journal-title":"Biomed Res Int"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1111\/j.1445-5994.1993.tb04720.x","article-title":"Systemic lupus erythematosus in Australian aborigines: high prevalence, morbidity and mortality","volume":"23","author":"Anstey NM","year":"1993","unstructured":"Anstey NM, Bastian I, Dunckley H, Currie BJ. Systemic lupus erythematosus in Australian aborigines: high prevalence, morbidity and mortality. Aust N Z J Med. 1993, 23:646-51. 10.1111\/j.1445-5994.1993.tb04720.x","journal-title":"Aust N Z J Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1111\/j.1445-5994.1995.tb02843.x","article-title":"Systemic lupus erythematosus (SLE): different prevalences in different populations of Australian aboriginals","volume":"25","author":"Grennan DM","year":"1995","unstructured":"Grennan DM, Bossingham D. Systemic lupus erythematosus (SLE): different prevalences in different populations of Australian aboriginals. Aust N Z J Med. 1995, 25:182-3. 10.1111\/j.1445-5994.1995.tb02843.x","journal-title":"Aust N Z J Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1191\/0961203306lu2305xx","article-title":"Epidemiology of systemic lupus erythematosus: a comparison of worldwide disease burden","volume":"15","author":"Danchenko N","year":"2006","unstructured":"Danchenko N, Satia JA, Anthony MS. Epidemiology of systemic lupus erythematosus: a comparison of worldwide disease burden. Lupus. 2006, 15:308-18. 10.1191\/0961203306lu2305xx","journal-title":"Lupus"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1002\/art.11105","article-title":"Sex hormones and systemic lupus erythematosus: review and meta-analysis","volume":"48","author":"McMurray RW","year":"2003","unstructured":"McMurray RW, May W. Sex hormones and systemic lupus erythematosus: review and meta-analysis. Arthritis Rheum. 2003, 48:2100-10. 10.1002\/art.11105","journal-title":"Arthritis Rheum"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1186\/s12969-020-00443-8","article-title":"Global prevalence estimates of three chronic musculoskeletal conditions: club foot, juvenile idiopathic arthritis and juvenile systemic lupus erythematosus","volume":"18","author":"Dave M","year":"2020","unstructured":"Dave M, Rankin J, Pearce M, Foster HE. Global prevalence estimates of three chronic musculoskeletal conditions: club foot, juvenile idiopathic arthritis and juvenile systemic lupus erythematosus. Pediatr Rheumatol Online J. 2020, 18:49. 10.1186\/s12969-020-00443-8","journal-title":"Pediatr Rheumatol Online J"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1177\/0961203316660625","article-title":"Severe disease presentation and poor outcomes among pediatric systemic lupus erythematosus patients in South Africa","volume":"26","author":"Lewandowski LB","year":"2017","unstructured":"Lewandowski LB, Schanberg LE, Thielman N, et al.. Severe disease presentation and poor outcomes among pediatric systemic lupus erythematosus patients in South Africa. Lupus. 2017, 26:186-94. 10.1177\/0961203316660625","journal-title":"Lupus"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1177\/0961203318791046","article-title":"Outcomes in juvenile onset lupus: single center cohort from a developing country","volume":"27","author":"Aggarwal A","year":"2018","unstructured":"Aggarwal A, Phatak S, Srivastava P, Lawrence A, Agarwal V, Misra R. Outcomes in juvenile onset lupus: single center cohort from a developing country. Lupus. 2018, 27:1867-75. 10.1177\/0961203318791046","journal-title":"Lupus"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ncl.2009.09.004","article-title":"Neurologic manifestations of systemic lupus erythematosus in children and adults","volume":"28","author":"Muscal E","year":"2010","unstructured":"Muscal E, Brey RL. Neurologic manifestations of systemic lupus erythematosus in children and adults. Neurol Clin. 2010, 28:61-73. 10.1016\/j.ncl.2009.09.004","journal-title":"Neurol Clin"},{"key":"ref12","article-title":"The incidence and prevalence of neuropsychiatric syndromes in pediatric onset systemic lupus erythematosus","volume":"29","author":"Sibbitt WL Jr","year":"2002","unstructured":"Sibbitt WL Jr, Brandt JR, Johnson CR, et al.. The incidence and prevalence of neuropsychiatric syndromes in pediatric onset systemic lupus erythematosus. J Rheumatol. 2002, 29:1536-42.","journal-title":"J Rheumatol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2016.06.013","article-title":"The diagnosis and clinical management of the neuropsychiatric manifestations of lupus","volume":"74","author":"Govoni M","year":"2016","unstructured":"Govoni M, Bortoluzzi A, Padovan M, et al.. The diagnosis and clinical management of the neuropsychiatric manifestations of lupus. J Autoimmun. 2016, 74:41-72. 10.1016\/j.jaut.2016.06.013","journal-title":"J Autoimmun"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2010.08.001","article-title":"Neuropsychiatric syndromes in systemic lupus erythematosus: a meta-analysis","volume":"41","author":"Unterman A","year":"2011","unstructured":"Unterman A, Nolte JE, Boaz M, Abady M, Shoenfeld Y, Zandman-Goddard G. Neuropsychiatric syndromes in systemic lupus erythematosus: a meta-analysis. Semin Arthritis Rheum. 2011, 41:1-11. 10.1016\/j.semarthrit.2010.08.001","journal-title":"Semin Arthritis Rheum"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(199904)42:4<599::AID-ANR2>3.0.CO;2-F","article-title":"The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes","volume":"42","year":"1999","unstructured":"The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum. 1999, 42.599-608. 10.1002\/1529-0131(199904)42:4&lt;599::AID-ANR2&gt;3.0.CO;2-F","journal-title":"Arthritis Rheum"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.58.8.1214","article-title":"Neuropsychiatric syndromes in lupus: prevalence using standardized definitions","volume":"58","author":"Brey RL","year":"2002","unstructured":"Brey RL, Holliday SL, Saklad AR, et al.. Neuropsychiatric syndromes in lupus: prevalence using standardized definitions. Neurology. 2002, 58:1214-20. 10.1212\/wnl.58.8.1214","journal-title":"Neurology"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1080\/00325481.2018.1492309","article-title":"Diagnostic approach to neuropsychiatric lupus erythematosus: what should we do?","volume":"130","author":"Zardi EM","year":"2018","unstructured":"Zardi EM, Giorgi C, Zardi DM. Diagnostic approach to neuropsychiatric lupus erythematosus: what should we do?. Postgrad Med. 2018, 130:536-47. 10.1080\/00325481.2018.1492309","journal-title":"Postgrad Med"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202369","article-title":"Neuropsychiatric manifestations in patients with systemic lupus erythematosus: epidemiology and radiology pointing to an immune-mediated cause","volume":"72","author":"Steup-Beekman GM","year":"2013","unstructured":"Steup-Beekman GM, Zirkzee EJ, Cohen D, et al.. Neuropsychiatric manifestations in patients with systemic lupus erythematosus: epidemiology and radiology pointing to an immune-mediated cause. Ann Rheum Dis. 2013, 72:76-9. 10.1136\/annrheumdis-2012-202369","journal-title":"Ann Rheum Dis"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-015-0534-3","article-title":"Management of neuropsychiatric systemic lupus erythematosus: current approaches and future perspectives","volume":"76","author":"Magro-Checa C","year":"2016","unstructured":"Magro-Checa C, Zirkzee EJ, Huizinga TW, Steup-Beekman GM. Management of neuropsychiatric systemic lupus erythematosus: current approaches and future perspectives. Drugs. 2016, 76:459-83. 10.1007\/s40265-015-0534-3","journal-title":"Drugs"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(76)90431-9","article-title":"The bimodal mortality pattern of systemic lupus erythematosus","volume":"60","author":"Urowitz MB","year":"1976","unstructured":"Urowitz MB, Bookman AA, Koehler BE, Gordon DA, Smythe HA, Ogryzlo MA. The bimodal mortality pattern of systemic lupus erythematosus. Am J Med. 1976, 60:221-5. 10.1016\/0002-9343(76)90431-9","journal-title":"Am J Med"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1002\/acr.23509","article-title":"Cerebrovascular events in systemic lupus erythematosus: results from an international inception cohort study","volume":"70","author":"Hanly JG","year":"2018","unstructured":"Hanly JG, Li Q, Su L, et al.. Cerebrovascular events in systemic lupus erythematosus: results from an international inception cohort study. Arthritis Care Res (Hoboken). 2018, 70:1478-87. 10.1002\/acr.23509","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-008-0921-1","article-title":"Association of anti-ribosomal P protein antibodies with neuropsychiatric and other manifestations of systemic lupus erythematosus","volume":"27","author":"Abdel-Nasser AM","year":"2008","unstructured":"Abdel-Nasser AM, Ghaleb RM, Mahmoud JA, Khairy W, Mahmoud RM. Association of anti-ribosomal P protein antibodies with neuropsychiatric and other manifestations of systemic lupus erythematosus. Clin Rheumatol. 2008, 27:1377-85. 10.1007\/s10067-008-0921-1","journal-title":"Clin Rheumatol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2011.04.001","article-title":"Peripheral neuropathy in patients with systemic lupus erythematosus","volume":"41","author":"Florica B","year":"2011","unstructured":"Florica B, Aghdassi E, Su J, Gladman DD, Urowitz MB, Fortin PR. Peripheral neuropathy in patients with systemic lupus erythematosus. Semin Arthritis Rheum. 2011, 41:203-11. 10.1016\/j.semarthrit.2011.04.001","journal-title":"Semin Arthritis Rheum"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198707303170503","article-title":"Association between lupus psychosis and anti-ribosomal P protein antibodies","volume":"317","author":"Bonfa E","year":"1987","unstructured":"Bonfa E, Golombek SJ, Kaufman LD, Skelly S, Weissbach H, Brot N, Elkon KB. Association between lupus psychosis and anti-ribosomal P protein antibodies. N Engl J Med. 1987, 317:265-71. 10.1056\/NEJM198707303170503","journal-title":"N Engl J Med"},{"key":"ref25","article-title":"Neuropsychiatric manifestations in systemic lupus erythematosus: prevalence and association with antiphospholipid antibodies","volume":"30","author":"Sanna G","year":"2003","unstructured":"Sanna G, Bertolaccini ML, Cuadrado MJ, Laing H, Khamashta MA, Mathieu A, Hughes GR. Neuropsychiatric manifestations in systemic lupus erythematosus: prevalence and association with antiphospholipid antibodies. J Rheumatol. 2003, 30:985-92.","journal-title":"J Rheumatol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1002\/art.20156","article-title":"Antibodies to microtubule-associated protein 2 in patients with neuropsychiatric systemic lupus erythematosus","volume":"50","author":"Williams RC Jr","year":"2004","unstructured":"Williams RC Jr, Sugiura K, Tan EM. Antibodies to microtubule-associated protein 2 in patients with neuropsychiatric systemic lupus erythematosus. Arthritis Rheum. 2004, 50:1239-47. 10.1002\/art.20156","journal-title":"Arthritis Rheum"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1186\/ar1198","article-title":"Autoantibody profile in systemic lupus erythematosus with psychiatric manifestations: a role for anti-endothelial-cell antibodies","volume":"6","author":"Conti F","year":"2004","unstructured":"Conti F, Alessandri C, Bompane D, Bombardieri M, Spinelli FR, Rusconi AC, Valesini G. Autoantibody profile in systemic lupus erythematosus with psychiatric manifestations: a role for anti-endothelial-cell antibodies. Arthritis Res Ther. 2004, 6:366-72. 10.1186\/ar1198","journal-title":"Arthritis Res Ther"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1002\/art.39750","article-title":"Anti-GAPDH autoantibodies as a pathogenic determinant and potential biomarker of neuropsychiatric diseases","volume":"68","author":"Delunardo F","year":"2016","unstructured":"Delunardo F, Soldati D, Bellisario V, et al.. Anti-GAPDH autoantibodies as a pathogenic determinant and potential biomarker of neuropsychiatric diseases. Arthritis Rheumatol. 2016, 68:2708-16. 10.1002\/art.39750","journal-title":"Arthritis Rheumatol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1136\/ard.59.2.120","article-title":"Transverse myelopathy in systemic lupus erythematosus: an analysis of 14 cases and review of the literature","volume":"59","author":"Kovacs B","year":"2000","unstructured":"Kovacs B, Lafferty TL, Brent LH, DeHoratius RJ. Transverse myelopathy in systemic lupus erythematosus: an analysis of 14 cases and review of the literature. Ann Rheum Dis. 2000, 59:120-4. 10.1136\/ard.59.2.120","journal-title":"Ann Rheum Dis"},{"key":"ref30","article-title":"Acute transverse myelopathy in systemic lupus erythematosus: clinical presentation, treatment, and outcome","volume":"25","author":"Mok CC","year":"1998","unstructured":"Mok CC, Lau CS, Chan EY, Wong RW. Acute transverse myelopathy in systemic lupus erythematosus: clinical presentation, treatment, and outcome. J Rheumatol. 1998, 25:467-73.","journal-title":"J Rheumatol"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1177\/096120339600500409","article-title":"Transverse myelopathy in SLE: clinical features and functional outcomes","volume":"5","author":"Chan KF","year":"1996","unstructured":"Chan KF, Boey ML. Transverse myelopathy in SLE: clinical features and functional outcomes. Lupus. 1996, 5:294-9. 10.1177\/096120339600500409","journal-title":"Lupus"},{"key":"ref32","article-title":"Myelitis in the course of systemic lupus erythematosus: review","volume":"119","author":"\u0141ukjanowicz M","year":"2009","unstructured":"\u0141ukjanowicz M, Brzosko M. Myelitis in the course of systemic lupus erythematosus: review. Pol Arch Med Wewn. 2009, 119:67-72.","journal-title":"Pol Arch Med Wewn"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2005.20.6.1085","article-title":"A catastrophic-onset longitudinal myelitis accompanied by bilateral internuclear ophthalmoplegia in a patient with systemic lupus erythematosus","volume":"20","author":"Rheu CW","year":"2005","unstructured":"Rheu CW, Lee SI, Yoo WH. A catastrophic-onset longitudinal myelitis accompanied by bilateral internuclear ophthalmoplegia in a patient with systemic lupus erythematosus. J Korean Med Sci. 2005, 20:1085-8. 10.3346\/jkms.2005.20.6.1085","journal-title":"J Korean Med Sci"},{"key":"ref34","article-title":"Recurrent aseptic meningitis followed by transverse myelitis as a presentation of systemic lupus erythematosus","volume":"15","author":"Sands ML","year":"1988","unstructured":"Sands ML, Ryczak M, Brown RB. Recurrent aseptic meningitis followed by transverse myelitis as a presentation of systemic lupus erythematosus. J Rheumatol. 1988, 15:862-4.","journal-title":"J Rheumatol"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/31.8.555","article-title":"Transverse myelitis in systemic lupus erythematosus: two cases with magnetic resonance imaging","volume":"31","author":"Simeon-Aznar CP","year":"1992","unstructured":"Simeon-Aznar CP, Tolosa-Vilella C, Cuenca-Luque R, Jordana-Comajuncosa R, Ordi-Ros J, Bosch-Gil JA. Transverse myelitis in systemic lupus erythematosus: two cases with magnetic resonance imaging. Br J Rheumatol. 1992, 31:555-8. 10.1093\/rheumatology\/31.8.555","journal-title":"Br J Rheumatol"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1136\/ard.48.6.512","article-title":"Acute transverse myelopathy complicating systemic lupus erythematosus","volume":"48","author":"Propper DJ","year":"1989","unstructured":"Propper DJ, Bucknall RC. Acute transverse myelopathy complicating systemic lupus erythematosus. Ann Rheum Dis. 1989, 48:512-5. 10.1136\/ard.48.6.512","journal-title":"Ann Rheum Dis"},{"key":"ref37","article-title":"Transverse myelitis in systemic lupus erythematosus--the effect of IV pulse methylprednisolone and cyclophosphamide","volume":"19","author":"Barile L","year":"1992","unstructured":"Barile L, Lavalle C. Transverse myelitis in systemic lupus erythematosus--the effect of IV pulse methylprednisolone and cyclophosphamide. J Rheumatol. 1992, 19:370-2.","journal-title":"J Rheumatol"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1007\/BF00878876","article-title":"Lupus transverse myelopathy: better outcome with early recognition and aggressive high-dose intravenous corticosteroid pulse treatment","volume":"242","author":"Harisdangkul V","year":"1995","unstructured":"Harisdangkul V, Doorenbos D, Subramony SH. Lupus transverse myelopathy: better outcome with early recognition and aggressive high-dose intravenous corticosteroid pulse treatment. J Neurol. 1995, 242:326-31. 10.1007\/BF00878876","journal-title":"J Neurol"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2017.04.008","article-title":"The blood brain barrier and neuropsychiatric lupus: new perspectives in light of advances in understanding the neuroimmune interface","volume":"16","author":"Stock AD","year":"2017","unstructured":"Stock AD, Gelb S, Pasternak O, Ben-Zvi A, Putterman C. The blood brain barrier and neuropsychiatric lupus: new perspectives in light of advances in understanding the neuroimmune interface. Autoimmun Rev. 2017, 16:612-9. 10.1016\/j.autrev.2017.04.008","journal-title":"Autoimmun Rev"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1096\/fj.09-138834","article-title":"C5a alters blood-brain barrier integrity in experimental lupus","volume":"24","author":"Jacob A","year":"2010","unstructured":"Jacob A, Hack B, Chiang E, Garcia JG, Quigg RJ, Alexander JJ. C5a alters blood-brain barrier integrity in experimental lupus. FASEB J. 2010, 24:1682-8. 10.1096\/fj.09-138834","journal-title":"FASEB J"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-4159.2011.07490.x","article-title":"C5a\/CD88 signaling alters blood-brain barrier integrity in lupus through nuclear factor-\u03baB","volume":"119","author":"Jacob A","year":"2011","unstructured":"Jacob A, Hack B, Chen P, Quigg RJ, Alexander JJ. C5a\/CD88 signaling alters blood-brain barrier integrity in lupus through nuclear factor-\u03baB. J Neurochem. 2011, 119:1041-51. 10.1111\/j.1471-4159.2011.07490.x","journal-title":"J Neurochem"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-015-0269-8","article-title":"Neuropsychiatric lupus: a mosaic of clinical presentations","volume":"13","author":"Kivity S","year":"2015","unstructured":"Kivity S, Agmon-Levin N, Zandman-Goddard G, Chapman J, Shoenfeld Y. Neuropsychiatric lupus: a mosaic of clinical presentations. BMC Med. 2015, 13:43. 10.1186\/s12916-015-0269-8","journal-title":"BMC Med"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1177\/0961203316629556","article-title":"IL-6, IL-8, IP-10, MCP-1 and G-CSF are significantly increased in cerebrospinal fluid but not in sera of patients with central neuropsychiatric lupus erythematosus","volume":"25","author":"Yoshio T","year":"2016","unstructured":"Yoshio T, Okamoto H, Kurasawa K, Dei Y, Hirohata S, Minota S. IL-6, IL-8, IP-10, MCP-1 and G-CSF are significantly increased in cerebrospinal fluid but not in sera of patients with central neuropsychiatric lupus erythematosus. Lupus. 2016, 25:997-1003. 10.1177\/0961203316629556","journal-title":"Lupus"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2024.156770","article-title":"Chemokines and chemokine receptors: potential therapeutic targets in systemic lupus erythematosus","volume":"184","author":"Duan L","year":"2024","unstructured":"Duan L, Yao Y, Kong H, Zhou Y, Cui D. Chemokines and chemokine receptors: potential therapeutic targets in systemic lupus erythematosus. Cytokine. 2024, 184:156770. 10.1016\/j.cyto.2024.156770","journal-title":"Cytokine"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.182.2.1192","article-title":"Potent induction of IFN-alpha and chemokines by autoantibodies in the cerebrospinal fluid of patients with neuropsychiatric lupus","volume":"182","author":"Santer DM","year":"2009","unstructured":"Santer DM, Yoshio T, Minota S, M\u00f6ller T, Elkon KB. Potent induction of IFN-alpha and chemokines by autoantibodies in the cerebrospinal fluid of patients with neuropsychiatric lupus. J Immunol. 2009, 182:1192-201. 10.4049\/jimmunol.182.2.1192","journal-title":"J Immunol"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1038\/nature22821","article-title":"Microglia-dependent synapse loss in type I interferon-mediated lupus","volume":"546","author":"Bialas AR","year":"2017","unstructured":"Bialas AR, Presumey J, Das A, et al.. Microglia-dependent synapse loss in type I interferon-mediated lupus. Nature. 2017, 546:539-43. 10.1038\/nature22821","journal-title":"Nature"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1002\/acr2.11217","article-title":"Role of serum IL-6 in neuropsychiatric systemic lupus erythematosus","volume":"3","author":"Hirohata S","year":"2021","unstructured":"Hirohata S, Kikuchi H. Role of serum IL-6 in neuropsychiatric systemic lupus erythematosus. ACR Open Rheumatol. 2021, 3:42-9. 10.1002\/acr2.11217","journal-title":"ACR Open Rheumatol"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2021.577620","article-title":"Hippocampal microglia CD40 mediates NPSLE cognitive dysfunction in mice","volume":"357","author":"Qiao X","year":"2021","unstructured":"Qiao X, Wang H, Lu L, et al.. Hippocampal microglia CD40 mediates NPSLE cognitive dysfunction in mice. J Neuroimmunol. 2021, 357:577620. 10.1016\/j.jneuroim.2021.577620","journal-title":"J Neuroimmunol"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-014-7406-8","article-title":"Autoantibodies involved in neuropsychiatric manifestations associated with systemic lupus erythematosus: a systematic review","volume":"261","author":"Sciascia S","year":"2014","unstructured":"Sciascia S, Bertolaccini ML, Roccatello D, Khamashta MA, Sanna G. Autoantibodies involved in neuropsychiatric manifestations associated with systemic lupus erythematosus: a systematic review. J Neurol. 2014, 261:1706-14. 10.1007\/s00415-014-7406-8","journal-title":"J Neurol"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1177\/0961203308090025","article-title":"Pathogenic role of antiphospholipid antibodies","volume":"17","author":"Salmon JE","year":"2008","unstructured":"Salmon JE, de Groot PG. Pathogenic role of antiphospholipid antibodies. Lupus. 2008, 17:405-11. 10.1177\/0961203308090025","journal-title":"Lupus"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.2217\/ijr.11.9","article-title":"Pathophysiological mechanisms in antiphospholipid syndrome","volume":"6","author":"Harper BE","year":"2011","unstructured":"Harper BE, Wills R, Pierangeli SS. Pathophysiological mechanisms in antiphospholipid syndrome. Int J Clin Rheumtol. 2011, 6:157-71. 10.2217\/ijr.11.9","journal-title":"Int J Clin Rheumtol"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2014.04.003","article-title":"Antibody-specific behavioral effects: intracerebroventricular injection of antiphospholipid antibodies induces hyperactive behavior while anti-ribosomal-P antibodies induces depression and smell deficits in mice","volume":"272","author":"Katzav A","year":"2014","unstructured":"Katzav A, Ben-Ziv T, Blank M, Pick CG, Shoenfeld Y, Chapman J. Antibody-specific behavioral effects: intracerebroventricular injection of antiphospholipid antibodies induces hyperactive behavior while anti-ribosomal-P antibodies induces depression and smell deficits in mice. J Neuroimmunol. 2014, 272:10-5. 10.1016\/j.jneuroim.2014.04.003","journal-title":"J Neuroimmunol"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/981519","article-title":"Seizures in primary antiphospholipid syndrome: the relevance of smoking to stroke","volume":"2012","author":"de Carvalho JF","year":"2012","unstructured":"de Carvalho JF, Pasoto SG, Appenzeller S. Seizures in primary antiphospholipid syndrome: the relevance of smoking to stroke. Clin Dev Immunol. 2012, 2012:981519. 10.1155\/2012\/981519","journal-title":"Clin Dev Immunol"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1186\/s42358-020-00148-2","article-title":"The diagnostic benefit of antibodies against ribosomal proteins in systemic lupus erythematosus","volume":"60","author":"Shi ZR","year":"2020","unstructured":"Shi ZR, Han YF, Yin J, et al.. The diagnostic benefit of antibodies against ribosomal proteins in systemic lupus erythematosus. Adv Rheumatol. 2020, 60:45. 10.1186\/s42358-020-00148-2","journal-title":"Adv Rheumatol"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2249.1998.00545.x","article-title":"Anti-ribosomal antibodies bind the Sm proteins D and B\/B'","volume":"112","author":"Caponi L","year":"1998","unstructured":"Caponi L, Bombardieri S, Migliorini P. Anti-ribosomal antibodies bind the Sm proteins D and B\/B'. Clin Exp Immunol. 1998, 112:139-43. 10.1046\/j.1365-2249.1998.00545.x","journal-title":"Clin Exp Immunol"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1186\/s13041-022-00937-4","article-title":"Blood-brain barrier: emerging trends on transport models and new-age strategies for therapeutics intervention against neurological disorders","volume":"15","author":"Alajangi HK","year":"2022","unstructured":"Alajangi HK, Kaur M, Sharma A, et al.. Blood-brain barrier: emerging trends on transport models and new-age strategies for therapeutics intervention against neurological disorders. Mol Brain. 2022, 15:49. 10.1186\/s13041-022-00937-4","journal-title":"Mol Brain"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcibr0902052","article-title":"Memory and the NMDA receptors","volume":"361","author":"Li F","year":"2009","unstructured":"Li F, Tsien JZ. Memory and the NMDA receptors. N Engl J Med. 2009, 361:302-3. 10.1056\/NEJMcibr0902052","journal-title":"N Engl J Med"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1007\/s00702-014-1193-3","article-title":"Glutamate receptor antibodies in neurological diseases: anti-AMPA-GluR3 antibodies, anti-NMDA-NR1 antibodies, anti-NMDA-NR2A\/B antibodies, anti-mGluR1 antibodies or anti-mGluR5 antibodies are present in subpopulations of patients with either: epilepsy, encephalitis, cerebellar ataxia, systemic lupus erythematosus (SLE) and neuropsychiatric SLE, Sjogren's syndrome, schizophrenia, mania or stroke. These autoimmune anti-glutamate receptor antibodies can bind neurons in few brain regions, activate glutamate receptors, decrease glutamate receptor's expression, impair glutamate-induced signaling and function, activate blood brain barrier endothelial cells, kill neurons, damage the brain, induce behavioral\/psychiatric\/cognitive abnormalities and ataxia in animal models, and can be removed or silenced in some patients by immunotherapy","volume":"121","author":"Levite M","year":"2014","unstructured":"Levite M. Glutamate receptor antibodies in neurological diseases: anti-AMPA-GluR3 antibodies, anti-NMDA-NR1 antibodies, anti-NMDA-NR2A\/B antibodies, anti-mGluR1 antibodies or anti-mGluR5 antibodies are present in subpopulations of patients with either: epilepsy, encephalitis, cerebellar ataxia, systemic lupus erythematosus (SLE) and neuropsychiatric SLE, Sjogren's syndrome, schizophrenia, mania or stroke. These autoimmune anti-glutamate receptor antibodies can bind neurons in few brain regions, activate glutamate receptors, decrease glutamate receptor's expression, impair glutamate-induced signaling and function, activate blood brain barrier endothelial cells, kill neurons, damage the brain, induce behavioral\/psychiatric\/cognitive abnormalities and ataxia in animal models, and can be removed or silenced in some patients by immunotherapy. J Neural Transm (Vienna). 2014, 121:1029-75. 10.1007\/s00702-014-1193-3","journal-title":"J Neural Transm (Vienna)"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M703539200","article-title":"Formation of NR1\/NR2 and NR1\/NR3 heterodimers constitutes the initial step in N-methyl-D-aspartate receptor assembly","volume":"283","author":"Sch\u00fcler T","year":"2008","unstructured":"Sch\u00fcler T, Mesic I, Madry C, Bartholom\u00e4us I, Laube B. Formation of NR1\/NR2 and NR1\/NR3 heterodimers constitutes the initial step in N-methyl-D-aspartate receptor assembly. J Biol Chem. 2008, 283:37-46. 10.1074\/jbc.M703539200","journal-title":"J Biol Chem"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.1007\/s00737-020-01088-y","article-title":"Systemic lupus erythematosus associated with recurrent anti-NMDA receptor encephalitis during pregnancy","volume":"24","author":"Zhang S","year":"2021","unstructured":"Zhang S, Yang Y, Long T, Li Z. Systemic lupus erythematosus associated with recurrent anti-NMDA receptor encephalitis during pregnancy. Arch Womens Ment Health. 2021, 24:525-8. 10.1007\/s00737-020-01088-y","journal-title":"Arch Womens Ment Health"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2009.04.004","article-title":"Anti-aquaporin-4 auto-antibodies orchestrate the pathogenesis in neuromyelitis optica","volume":"9","author":"Saikali P","year":"2009","unstructured":"Saikali P, Cayrol R, Vincent T. Anti-aquaporin-4 auto-antibodies orchestrate the pathogenesis in neuromyelitis optica. Autoimmun Rev. 2009, 9:132-5. 10.1016\/j.autrev.2009.04.004","journal-title":"Autoimmun Rev"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.1080\/14737175.2020.1764352","article-title":"Moving beyond anti-aquaporin-4 antibodies: emerging biomarkers in the spectrum of neuromyelitis optica","volume":"20","author":"Rocca MA","year":"2020","unstructured":"Rocca MA, Cacciaguerra L, Filippi M. Moving beyond anti-aquaporin-4 antibodies: emerging biomarkers in the spectrum of neuromyelitis optica. Expert Rev Neurother. 2020, 20:601-18. 10.1080\/14737175.2020.1764352","journal-title":"Expert Rev Neurother"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.1177\/1352458517699791","article-title":"Aquaporin-4-autoimmunity in patients with systemic lupus erythematosus: a predominantly population-based study","volume":"24","author":"Asgari N","year":"2018","unstructured":"Asgari N, Jarius S, Laustrup H, Skejoe HP, Lillevang ST, Weinshenker BG, Voss A. Aquaporin-4-autoimmunity in patients with systemic lupus erythematosus: a predominantly population-based study. Mult Scler. 2018, 24:331-9. 10.1177\/1352458517699791","journal-title":"Mult Scler"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.cb.11.110195.000445","article-title":"Vasculogenesis","volume":"11","author":"Risau W","year":"1995","unstructured":"Risau W, Flamme I. Vasculogenesis. Annu Rev Cell Dev Biol. 1995, 11:73-91. 10.1146\/annurev.cb.11.110195.000445","journal-title":"Annu Rev Cell Dev Biol"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.1186\/s12950-023-00342-1","article-title":"Dysregulated endothelial cell markers in systemic lupus erythematosus: a systematic review and meta-analysis","volume":"20","author":"Bergkamp SC","year":"2023","unstructured":"Bergkamp SC, Wahadat MJ, Salah A, et al.. Dysregulated endothelial cell markers in systemic lupus erythematosus: a systematic review and meta-analysis. J Inflamm (Lond). 2023, 20:18. 10.1186\/s12950-023-00342-1","journal-title":"J Inflamm (Lond)"},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.849086","article-title":"Endothelial dysfunction in systemic lupus erythematosus and systemic sclerosis: a common trigger for different microvascular diseases","volume":"9","author":"Moschetti L","year":"2022","unstructured":"Moschetti L, Piantoni S, Vizzardi E, Sciatti E, Riccardi M, Franceschini F, Cavazzana I. Endothelial dysfunction in systemic lupus erythematosus and systemic sclerosis: a common trigger for different microvascular diseases. Front Med (Lausanne). 2022, 9:849086. 10.3389\/fmed.2022.849086","journal-title":"Front Med (Lausanne)"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.17969","article-title":"Neuropsychiatric systemic lupus erythematosus: a 2021 update on diagnosis, management, and current challenges","volume":"13","author":"Sarwar S","year":"2021","unstructured":"Sarwar S, Mohamed AS, Rogers S, et al.. Neuropsychiatric systemic lupus erythematosus: a 2021 update on diagnosis, management, and current challenges. Cureus. 2021, 13:17969. 10.7759\/cureus.17969","journal-title":"Cureus"},{"key":"ref68","doi-asserted-by":"publisher","DOI":"10.1080\/14397595.2019.1589912","article-title":"Prevalence, outcome and prognostic factors of neuropsychiatric systemic lupus erythematosus: a real world single center study","volume":"30","author":"Li X","year":"2020","unstructured":"Li X, Xiang X, Sun J, et al.. Prevalence, outcome and prognostic factors of neuropsychiatric systemic lupus erythematosus: a real world single center study. Mod Rheumatol. 2020, 30:321-6. 10.1080\/14397595.2019.1589912","journal-title":"Mod Rheumatol"},{"key":"ref69","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2022.998328","article-title":"Pathogenesis and treatment of neuropsychiatric systemic lupus erythematosus: a review","volume":"10","author":"Liu Y","year":"2022","unstructured":"Liu Y, Tu Z, Zhang X, Du K, Xie Z, Lin Z. Pathogenesis and treatment of neuropsychiatric systemic lupus erythematosus: a review. Front Cell Dev Biol. 2022, 10:998328. 10.3389\/fcell.2022.998328","journal-title":"Front Cell Dev Biol"},{"key":"ref70","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2013.00484","article-title":"Neuropsychiatric lupus, the blood brain barrier, and the TWEAK\/Fn14 pathway","volume":"4","author":"Stock AD","year":"2013","unstructured":"Stock AD, Wen J, Putterman C. Neuropsychiatric lupus, the blood brain barrier, and the TWEAK\/Fn14 pathway. Front Immunol. 2013, 4:484. 10.3389\/fimmu.2013.00484","journal-title":"Front Immunol"},{"key":"ref71","article-title":"The clinical significance of ubiquitin carboxyl hydrolase L1 and its autoantibody in neuropsychiatric systemic lupus erythematosus","volume":"37","author":"Li X","year":"2019","unstructured":"Li X, Sun J, Mu R, et al.. The clinical significance of ubiquitin carboxyl hydrolase L1 and its autoantibody in neuropsychiatric systemic lupus erythematosus. Clin Exp Rheumatol. 2019, 37:474-80.","journal-title":"Clin Exp Rheumatol"},{"key":"ref72","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.1657-18.2019","article-title":"Neuronal BC RNA transport impairments caused by systemic lupus erythematosus autoantibodies","volume":"39","author":"Muslimov IA","year":"2019","unstructured":"Muslimov IA, Iacoangeli A, Eom T, et al.. Neuronal BC RNA transport impairments caused by systemic lupus erythematosus autoantibodies. J Neurosci. 2019, 39:7759-77. 10.1523\/JNEUROSCI.1657-18.2019","journal-title":"J Neurosci"},{"key":"ref73","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci12020192","article-title":"Biomarkers in neuropsychiatric systemic lupus erythematosus: a systematic literature review of the last decade","volume":"12","author":"Lindblom J","year":"2022","unstructured":"Lindblom J, Mohan C, Parodis I. Biomarkers in neuropsychiatric systemic lupus erythematosus: a systematic literature review of the last decade. Brain Sci. 2022, 12:192. 10.3390\/brainsci12020192","journal-title":"Brain Sci"},{"key":"ref74","doi-asserted-by":"publisher","DOI":"10.1186\/s10020-023-00612-x","article-title":"Newly discovered roles of triosephosphate isomerase including functions within the nucleus","volume":"29","author":"Myers TD","year":"2023","unstructured":"Myers TD, Palladino MJ. Newly discovered roles of triosephosphate isomerase including functions within the nucleus. Mol Med. 2023, 29:18. 10.1186\/s10020-023-00612-x","journal-title":"Mol Med"},{"key":"ref75","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-017-3653-2","article-title":"Association of anti-triosephosphate isomerase antibodies with aseptic meningitis in patients with neuropsychiatric systemic lupus erythematosus","volume":"36","author":"Sato S","year":"2017","unstructured":"Sato S, Yashiro M, Asano T, Kobayashi H, Watanabe H, Migita K. Association of anti-triosephosphate isomerase antibodies with aseptic meningitis in patients with neuropsychiatric systemic lupus erythematosus. Clin Rheumatol. 2017, 36:1655-9. 10.1007\/s10067-017-3653-2","journal-title":"Clin Rheumatol"},{"key":"ref76","doi-asserted-by":"publisher","DOI":"10.1016\/s0301-0082(99)00046-5","article-title":"Phosphorylation of microtubule-associated protein 2 (MAP2) and its relevance for the regulation of the neuronal cytoskeleton function","volume":"61","author":"S\u00e1nchez C","year":"2000","unstructured":"S\u00e1nchez C, D\u00edaz-Nido J, Avila J. Phosphorylation of microtubule-associated protein 2 (MAP2) and its relevance for the regulation of the neuronal cytoskeleton function. Prog Neurobiol. 2000, 61:133-68. 10.1016\/s0301-0082(99)00046-5","journal-title":"Prog Neurobiol"},{"key":"ref77","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2886","article-title":"Decreased expression of synapse-related genes and loss of synapses in major depressive disorder","volume":"18","author":"Kang HJ","year":"2012","unstructured":"Kang HJ, Voleti B, Hajszan T, et al.. Decreased expression of synapse-related genes and loss of synapses in major depressive disorder. Nat Med. 2012, 18:1413-7. 10.1038\/nm.2886","journal-title":"Nat Med"},{"key":"ref78","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/35.6.534","article-title":"Predominance of IgM anti-U1RNP antibodies in patients with systemic lupus erythematosus","volume":"35","author":"Vlachoyiannopoulos PG","year":"1996","unstructured":"Vlachoyiannopoulos PG, Guialis A, Tzioufas G, Moutsopoulos HM. Predominance of IgM anti-U1RNP antibodies in patients with systemic lupus erythematosus. Br J Rheumatol. 1996, 35:534-41. 10.1093\/rheumatology\/35.6.534","journal-title":"Br J Rheumatol"},{"key":"ref79","doi-asserted-by":"publisher","DOI":"10.3390\/antib5010002","article-title":"Autoantibodies in SLE: specificities, isotypes and receptors","volume":"5","author":"Dema B","year":"2016","unstructured":"Dema B, Charles N. Autoantibodies in SLE: specificities, isotypes and receptors. Antibodies (Basel). 2016, 5:2. 10.3390\/antib5010002","journal-title":"Antibodies (Basel)"},{"key":"ref80","doi-asserted-by":"publisher","DOI":"10.1148\/rg.210045","article-title":"Central nervous system systemic lupus erythematosus: pathophysiologic, clinical, and imaging features","volume":"42","author":"Ota Y","year":"2022","unstructured":"Ota Y, Srinivasan A, Capizzano AA, et al.. Central nervous system systemic lupus erythematosus: pathophysiologic, clinical, and imaging features. Radiographics. 2022, 42:212-32. 10.1148\/rg.210045","journal-title":"Radiographics"},{"key":"ref81","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-019-1744-5","article-title":"Roles of circular RNAs in immune regulation and autoimmune diseases","volume":"10","author":"Zhou Z","year":"2019","unstructured":"Zhou Z, Sun B, Huang S, Zhao L. Roles of circular RNAs in immune regulation and autoimmune diseases. Cell Death Dis. 2019, 10:503. 10.1038\/s41419-019-1744-5","journal-title":"Cell Death Dis"},{"key":"ref82","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.130476","article-title":"EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs","volume":"69","author":"Bertsias GK","year":"2010","unstructured":"Bertsias GK, Ioannidis JP, Aringer M, et al.. EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs. Ann Rheum Dis. 2010, 69:2074-82. 10.1136\/ard.2010.130476","journal-title":"Ann Rheum Dis"},{"key":"ref83","doi-asserted-by":"publisher","DOI":"10.1002\/acr.21691","article-title":"Cardiovascular disease and cognitive dysfunction in systemic lupus erythematosus","volume":"64","author":"Murray SG","year":"2012","unstructured":"Murray SG, Yazdany J, Kaiser R, et al.. Cardiovascular disease and cognitive dysfunction in systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2012, 64:1328-33. 10.1002\/acr.21691","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"ref84","doi-asserted-by":"publisher","DOI":"10.1097\/01.md.0000091181.93122.55","article-title":"Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients","volume":"82","author":"Cervera R","year":"2003","unstructured":"Cervera R, Khamashta MA, Font J, et al.. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine (Baltimore). 2003, 82:299-308. 10.1097\/01.md.0000091181.93122.55","journal-title":"Medicine (Baltimore)"},{"key":"ref85","article-title":"The necessity of stroke prevention in patients with systemic lupus erythematosus","volume":"17","author":"Saadatnia M","year":"2012","unstructured":"Saadatnia M, Sayed-Bonakdar Z, Mohammad-Sharifi G, Sarrami AH. The necessity of stroke prevention in patients with systemic lupus erythematosus. J Res Med Sci. 2012, 17:894-5.","journal-title":"J Res Med Sci"},{"key":"ref86","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2006.11.003","article-title":"Autoantibodies involved in neuropsychiatric SLE and antiphospholipid syndrome","volume":"36","author":"Zandman-Goddard G","year":"2007","unstructured":"Zandman-Goddard G, Chapman J, Shoenfeld Y. Autoantibodies involved in neuropsychiatric SLE and antiphospholipid syndrome. Semin Arthritis Rheum. 2007, 36:297-315. 10.1016\/j.semarthrit.2006.11.003","journal-title":"Semin Arthritis Rheum"},{"key":"ref87","doi-asserted-by":"publisher","DOI":"10.1002\/art.42624","article-title":"The 2023 ACR\/EULAR antiphospholipid syndrome classification criteria","volume":"75","author":"Barbhaiya M","year":"2023","unstructured":"Barbhaiya M, Zuily S, Naden R, et al.. The 2023 ACR\/EULAR antiphospholipid syndrome classification criteria. Arthritis Rheumatol. 2023, 75:1687-702. 10.1002\/art.42624","journal-title":"Arthritis Rheumatol"},{"key":"ref88","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1112830","article-title":"The pathogenesis of the antiphospholipid syndrome","volume":"368","author":"Giannakopoulos B","year":"2013","unstructured":"Giannakopoulos B, Krilis SA. The pathogenesis of the antiphospholipid syndrome. N Engl J Med. 2013, 368:1033-44. 10.1056\/NEJMra1112830","journal-title":"N Engl J Med"},{"key":"ref89","article-title":"Brain pathology in systemic lupus erythematosus","volume":"19","author":"Hanly JG","year":"1992","unstructured":"Hanly JG, Walsh NM, Sangalang V. Brain pathology in systemic lupus erythematosus. J Rheumatol. 1992, 19:732-41.","journal-title":"J Rheumatol"},{"key":"ref90","doi-asserted-by":"publisher","DOI":"10.1016\/s0049-0172(79)80009-8","article-title":"Central nervous system involvement in systemic lupus erythematosus: a review of neuropathologic findings in 57 cases, 1955--1977","volume":"8","author":"Ellis SG","year":"1979","unstructured":"Ellis SG, Verity MA. Central nervous system involvement in systemic lupus erythematosus: a review of neuropathologic findings in 57 cases, 1955--1977. Semin Arthritis Rheum. 1979, 8:212-21. 10.1016\/s0049-0172(79)80009-8","journal-title":"Semin Arthritis Rheum"},{"key":"ref91","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kew341","article-title":"Brain histopathology in patients with systemic lupus erythematosus: identification of lesions associated with clinical neuropsychiatric lupus syndromes and the role of complement","volume":"56","author":"Cohen D","year":"2017","unstructured":"Cohen D, Rijnink EC, Nabuurs RJ, et al.. Brain histopathology in patients with systemic lupus erythematosus: identification of lesions associated with clinical neuropsychiatric lupus syndromes and the role of complement. Rheumatology (Oxford). 2017, 56:77-86. 10.1093\/rheumatology\/kew341","journal-title":"Rheumatology (Oxford)"},{"key":"ref92","doi-asserted-by":"publisher","DOI":"10.1002\/art.11296","article-title":"Risk factors for coronary heart disease in women with systemic lupus erythematosus: the Toronto Risk Factor Study","volume":"48","author":"Bruce IN","year":"2003","unstructured":"Bruce IN, Urowitz MB, Gladman DD, Iba\u00f1ez D, Steiner G. Risk factors for coronary heart disease in women with systemic lupus erythematosus: the Toronto Risk Factor Study. Arthritis Rheum. 2003, 48:3159-67. 10.1002\/art.11296","journal-title":"Arthritis Rheum"},{"key":"ref93","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2015-000168","article-title":"Stroke in systemic lupus erythematosus: a meta-analysis of population-based cohort studies","volume":"1","author":"Holmqvist M","year":"2015","unstructured":"Holmqvist M, Simard JF, Asplund K, Arkema EV. Stroke in systemic lupus erythematosus: a meta-analysis of population-based cohort studies. RMD Open. 2015, 1:e000168. 10.1136\/rmdopen-2015-000168","journal-title":"RMD Open"},{"key":"ref94","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(199902)42:2<338::AID-ANR17>3.0.CO;2-U","article-title":"Premature morbidity from cardiovascular and cerebrovascular diseases in women with systemic lupus erythematosus","volume":"42","author":"Ward MM","year":"1999","unstructured":"Ward MM. Premature morbidity from cardiovascular and cerebrovascular diseases in women with systemic lupus erythematosus. Arthritis Rheum. 1999, 42:338-46. 10.1002\/1529-0131(199902)42:2&lt;338::AID-ANR17&gt;3.0.CO;2-U","journal-title":"Arthritis Rheum"},{"key":"ref95","doi-asserted-by":"publisher","DOI":"10.1161\/01.STR.0000254476.05620.14","article-title":"Baseline disease activity, hyperlipidemia, and hypertension are predictive factors for ischemic stroke and stroke severity in systemic lupus erythematosus","volume":"38","author":"Mikdashi J","year":"2007","unstructured":"Mikdashi J, Handwerger B, Langenberg P, Miller M, Kittner S. Baseline disease activity, hyperlipidemia, and hypertension are predictive factors for ischemic stroke and stroke severity in systemic lupus erythematosus. Stroke. 2007, 38:281-5. 10.1161\/01.STR.0000254476.05620.14","journal-title":"Stroke"},{"key":"ref96","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20122","article-title":"Atherosclerotic vascular events in a multinational inception cohort of systemic lupus erythematosus","volume":"62","author":"Urowitz MB","year":"2010","unstructured":"Urowitz MB, Gladman D, Iba\u00f1ez D, et al.. Atherosclerotic vascular events in a multinational inception cohort of systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2010, 62:881-7. 10.1002\/acr.20122","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"ref97","doi-asserted-by":"publisher","DOI":"10.1001\/jama.291.5.576","article-title":"Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke","volume":"291","author":"Levine SR","year":"2004","unstructured":"Levine SR, Brey RL, Tilley BC, et al.. Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke. JAMA. 2004, 291:576-84. 10.1001\/jama.291.5.576","journal-title":"JAMA"},{"key":"ref98","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000001183","article-title":"Cardiovascular events in systemic lupus erythematosus: a nationwide study in Spain from the Relesser Registry","volume":"94","author":"Fern\u00e1ndez-Nebro A","year":"2015","unstructured":"Fern\u00e1ndez-Nebro A, R\u00faa-Figueroa \u00cd, L\u00f3pez-Longo FJ, et al.. Cardiovascular events in systemic lupus erythematosus: a nationwide study in Spain from the Relesser Registry. Medicine (Baltimore). 2015, 94:1183. 10.1097\/MD.0000000000001183","journal-title":"Medicine (Baltimore)"},{"key":"ref99","article-title":"Prevalence and prognosis of cerebrovascular accidents and its subtypes among patients with systemic lupus erythematosus in Isfahan, Iran: a hospital clinic-based study","volume":"5","author":"Saadatnia M","year":"2014","unstructured":"Saadatnia M, Sayed-Bonakdar Z, Mohammad-Sharifi G, Sarrami AH. Prevalence and prognosis of cerebrovascular accidents and its subtypes among patients with systemic lupus erythematosus in Isfahan, Iran: a hospital clinic-based study. Int J Prev Med. 2014, 5:123-6.","journal-title":"Int J Prev Med"},{"key":"ref100","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.150884","article-title":"Genetic variants that are associated with neuropsychiatric systemic lupus erythematosus","volume":"43","author":"Ho RC","year":"2016","unstructured":"Ho RC, Ong H, Thiaghu C, Lu Y, Ho CS, Zhang MW. Genetic variants that are associated with neuropsychiatric systemic lupus erythematosus. J Rheumatol. 2016, 43:541-51. 10.3899\/jrheum.150884","journal-title":"J Rheumatol"},{"key":"ref101","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.114157","article-title":"TREX1 gene variant in neuropsychiatric systemic lupus erythematosus","volume":"69","author":"de Vries B","year":"2010","unstructured":"de Vries B, Steup-Beekman GM, Haan J, et al.. TREX1 gene variant in neuropsychiatric systemic lupus erythematosus. Ann Rheum Dis. 2010, 69:1886-7. 10.1136\/ard.2009.114157","journal-title":"Ann Rheum Dis"},{"key":"ref102","doi-asserted-by":"publisher","DOI":"10.1038\/gene.2010.73","article-title":"Evaluation of the TREX1 gene in a large multi-ancestral lupus cohort","volume":"12","author":"Namjou B","year":"2011","unstructured":"Namjou B, Kothari PH, Kelly JA, et al.. Evaluation of the TREX1 gene in a large multi-ancestral lupus cohort. Genes Immun. 2011, 12:270-9. 10.1038\/gene.2010.73","journal-title":"Genes Immun"},{"key":"ref103","doi-asserted-by":"publisher","DOI":"10.1155\/2011\/273907","article-title":"Activation of type I interferon pathway in systemic lupus erythematosus: association with distinct clinical phenotypes","volume":"2011","author":"Karageorgas TP","year":"2011","unstructured":"Karageorgas TP, Tseronis DD, Mavragani CP. Activation of type I interferon pathway in systemic lupus erythematosus: association with distinct clinical phenotypes. J Biomed Biotechnol. 2011, 2011:273907. 10.1155\/2011\/273907","journal-title":"J Biomed Biotechnol"},{"key":"ref104","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-201760","article-title":"HLA-DRB1*04\/*13 alleles are associated with vascular disease and antiphospholipid antibodies in systemic lupus erythematosus","volume":"72","author":"Lundstr\u00f6m E","year":"2013","unstructured":"Lundstr\u00f6m E, Gustafsson JT, J\u00f6nsen A, et al.. HLA-DRB1*04\/*13 alleles are associated with vascular disease and antiphospholipid antibodies in systemic lupus erythematosus. Ann Rheum Dis. 2013, 72:1018-25. 10.1136\/annrheumdis-2012-201760","journal-title":"Ann Rheum Dis"},{"key":"ref105","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202351","article-title":"Recent insights into the genetic basis of systemic lupus erythematosus","volume":"72","author":"Rullo OJ","year":"2013","unstructured":"Rullo OJ, Tsao BP. Recent insights into the genetic basis of systemic lupus erythematosus. Ann Rheum Dis. 2013, 72:56-61. 10.1136\/annrheumdis-2012-202351","journal-title":"Ann Rheum Dis"},{"key":"ref106","doi-asserted-by":"publisher","DOI":"10.1038\/jhg.2011.49","article-title":"Cumulative association of eight susceptibility genes with systemic lupus erythematosus in a Japanese female population","volume":"56","author":"Koga M","year":"2011","unstructured":"Koga M, Kawasaki A, Ito I, et al.. Cumulative association of eight susceptibility genes with systemic lupus erythematosus in a Japanese female population. J Hum Genet. 2011, 56:503-7. 10.1038\/jhg.2011.49","journal-title":"J Hum Genet"},{"key":"ref107","doi-asserted-by":"publisher","DOI":"10.1097\/00002281-200109000-00005","article-title":"Role of viruses in systemic lupus erythematosus and Sj\u00f6gren syndrome","volume":"13","author":"James JA","year":"2001","unstructured":"James JA, Harley JB, Scofield RH. Role of viruses in systemic lupus erythematosus and Sj\u00f6gren syndrome. Curr Opin Rheumatol. 2001, 13:370-6. 10.1097\/00002281-200109000-00005","journal-title":"Curr Opin Rheumatol"},{"key":"ref108","doi-asserted-by":"publisher","DOI":"10.1016\/s0049-0172(96)80018-7","article-title":"Immunopathogenesis and spectrum of infections in systemic lupus erythematosus","volume":"25","author":"Iliopoulos AG","year":"1996","unstructured":"Iliopoulos AG, Tsokos GC. Immunopathogenesis and spectrum of infections in systemic lupus erythematosus. Semin Arthritis Rheum. 1996, 25:318-36. 10.1016\/s0049-0172(96)80018-7","journal-title":"Semin Arthritis Rheum"},{"key":"ref109","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-012-2372-x","article-title":"Causes and predictors of death in Brazilian lupus patients","volume":"33","author":"Telles RW","year":"2013","unstructured":"Telles RW, Lanna CC, Souza FL, Rodrigues LA, Reis RC, Ribeiro AL. Causes and predictors of death in Brazilian lupus patients. Rheumatol Int. 2013, 33:467-73. 10.1007\/s00296-012-2372-x","journal-title":"Rheumatol Int"},{"key":"ref110","doi-asserted-by":"publisher","DOI":"10.1136\/ard.62.1.50","article-title":"Infectious CNS disease as a differential diagnosis in systemic rheumatic diseases: three case reports and a review of the literature","volume":"62","author":"Warnatz K","year":"2003","unstructured":"Warnatz K, Peter HH, Schumacher M, et al.. Infectious CNS disease as a differential diagnosis in systemic rheumatic diseases: three case reports and a review of the literature. Ann Rheum Dis. 2003, 62:50-7. 10.1136\/ard.62.1.50","journal-title":"Ann Rheum Dis"},{"key":"ref111","doi-asserted-by":"publisher","DOI":"10.1016\/j.clineuro.2015.01.023","article-title":"Cryptococcal meningitis in Chinese patients with systemic lupus erythematosus","volume":"131","author":"Zhong Y","year":"2015","unstructured":"Zhong Y, Li M, Liu J, Zhang W, Peng F. Cryptococcal meningitis in Chinese patients with systemic lupus erythematosus. Clin Neurol Neurosurg. 2015, 131:59-63. 10.1016\/j.clineuro.2015.01.023","journal-title":"Clin Neurol Neurosurg"},{"key":"ref112","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-006-0424-x","article-title":"Clinical features, prognostic and risk factors of central nervous system infections in patients with systemic lupus erythematosus","volume":"26","author":"Yang CD","year":"2007","unstructured":"Yang CD, Wang XD, Ye S, Gu YY, Bao CD, Wang Y, Chen SL. Clinical features, prognostic and risk factors of central nervous system infections in patients with systemic lupus erythematosus. Clin Rheumatol. 2007, 26:895-901. 10.1007\/s10067-006-0424-x","journal-title":"Clin Rheumatol"},{"key":"ref113","doi-asserted-by":"publisher","DOI":"10.1177\/0961203309357061","article-title":"Intrathecal cytokine and chemokine profiling in neuropsychiatric lupus or lupus complicated with central nervous system infection","volume":"19","author":"Lu XY","year":"2010","unstructured":"Lu XY, Zhu CQ, Qian J, Chen XX, Ye S, Gu YY. Intrathecal cytokine and chemokine profiling in neuropsychiatric lupus or lupus complicated with central nervous system infection. Lupus. 2010, 19:689-95. 10.1177\/0961203309357061","journal-title":"Lupus"},{"key":"ref114","doi-asserted-by":"publisher","DOI":"10.1177\/0961203308090017","article-title":"Neuropsychiatric lupus and infectious triggers","volume":"17","author":"Zandman-Goddard G","year":"2008","unstructured":"Zandman-Goddard G, Berkun Y, Barzilai O, Boaz M, Ram M, Anaya JM, Shoenfeld Y. Neuropsychiatric lupus and infectious triggers. Lupus. 2008, 17:380-4. 10.1177\/0961203308090017","journal-title":"Lupus"},{"key":"ref115","doi-asserted-by":"publisher","DOI":"10.1136\/ard.51.6.726","article-title":"Effects of ultraviolet irradiation on natural killer cell function in systemic lupus erythematosus","volume":"51","author":"Nived O","year":"1992","unstructured":"Nived O, Johansson I, Sturfelt G. Effects of ultraviolet irradiation on natural killer cell function in systemic lupus erythematosus. Ann Rheum Dis. 1992, 51:726-30. 10.1136\/ard.51.6.726","journal-title":"Ann Rheum Dis"},{"key":"ref116","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0781.1997.tb00232.x","article-title":"In vitro spontaneous and UVB-induced lymphocyte apoptosis are not specific to SLE","volume":"13","author":"Abe M","year":"1997","unstructured":"Abe M, Ishikawa O, Miyachi Y, Kanai Y. In vitro spontaneous and UVB-induced lymphocyte apoptosis are not specific to SLE. Photodermatol Photoimmunol Photomed. 1997, 13:204-7. 10.1111\/j.1600-0781.1997.tb00232.x","journal-title":"Photodermatol Photoimmunol Photomed"},{"key":"ref117","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/35.10.1002","article-title":"Ultraviolet irradiation in systemic lupus erythematosus: friend or foe?","volume":"35","author":"Cohen MR","year":"1996","unstructured":"Cohen MR, Isenberg DA. Ultraviolet irradiation in systemic lupus erythematosus: friend or foe?. Br J Rheumatol. 1996, 35:1002-7. 10.1093\/rheumatology\/35.10.1002","journal-title":"Br J Rheumatol"},{"key":"ref118","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1747.1998.00253.x","article-title":"Aberrant timing in epidermal expression of inducible nitric oxide synthase after UV irradiation in cutaneous lupus erythematosus","volume":"111","author":"Kuhn A","year":"1998","unstructured":"Kuhn A, Fehsel K, Lehmann P, Krutmann J, Ruzicka T, Kolb-Bachofen V. Aberrant timing in epidermal expression of inducible nitric oxide synthase after UV irradiation in cutaneous lupus erythematosus. J Invest Dermatol. 1998, 111:149-53. 10.1046\/j.1523-1747.1998.00253.x","journal-title":"J Invest Dermatol"},{"key":"ref119","doi-asserted-by":"publisher","DOI":"10.1111\/1523-1747.ep12355599","article-title":"Pathomechanisms of photosensitive lupus erythematosus","volume":"100","author":"Norris DA","year":"1993","unstructured":"Norris DA. Pathomechanisms of photosensitive lupus erythematosus. J Invest Dermatol. 1993, 100:58S-68S. 10.1111\/1523-1747.ep12355599","journal-title":"J Invest Dermatol"},{"key":"ref120","article-title":"Longterm ultraviolet-A1 irradiation therapy in systemic lupus erythematosus","volume":"24","author":"Molina JF","year":"1997","unstructured":"Molina JF, McGrath H Jr. Longterm ultraviolet-A1 irradiation therapy in systemic lupus erythematosus. J Rheumatol. 1997, 24:1072-4.","journal-title":"J Rheumatol"},{"key":"ref121","doi-asserted-by":"publisher","DOI":"10.1196\/annals.1422.004","article-title":"Sun-induced life-threatening lupus nephritis","volume":"1108","author":"Schmidt E","year":"2007","unstructured":"Schmidt E, Tony HP, Br\u00f6cker EB, Kneitz C. Sun-induced life-threatening lupus nephritis. Ann N Y Acad Sci. 2007, 1108:35-40. 10.1196\/annals.1422.004","journal-title":"Ann N Y Acad Sci"},{"key":"ref122","article-title":"Lupus cerebritis after visiting a tanning salon","volume":"67","author":"Geara AS","year":"2009","unstructured":"Geara AS, Torbey E, El-imad B. Lupus cerebritis after visiting a tanning salon. Bull NYU Hosp Jt Dis. 2009, 67:391-3.","journal-title":"Bull NYU Hosp Jt Dis"},{"key":"ref123","article-title":"Drug-induced lupus","volume":"20","author":"Yung RL","year":"1994","unstructured":"Yung RL, Richardson BC. Drug-induced lupus. Rheum Dis Clin North Am. 1994, 20:61-86.","journal-title":"Rheum Dis Clin North Am"},{"key":"ref124","doi-asserted-by":"publisher","DOI":"10.1080\/08916930500285857","article-title":"Drug-induced lupus erythematosus","volume":"38","author":"Sarzi-Puttini P","year":"2005","unstructured":"Sarzi-Puttini P, Atzeni F, Capsoni F, Lubrano E, Doria A. Drug-induced lupus erythematosus. Autoimmunity. 2005, 38:507-18. 10.1080\/08916930500285857","journal-title":"Autoimmunity"},{"key":"ref125","doi-asserted-by":"publisher","DOI":"10.1016\/j.medcli.2009.04.035","article-title":"Drug-induced lupus (Article in Spanish)","volume":"135","author":"Aguirre Zamorano MA","year":"2010","unstructured":"Aguirre Zamorano MA, L\u00f3pez Pedrera R, Cuadrado Lozano MJ. Drug-induced lupus (Article in Spanish). Med Clin (Barc). 2010, 135:124-9. 10.1016\/j.medcli.2009.04.035","journal-title":"Med Clin (Barc)"},{"key":"ref126","doi-asserted-by":"publisher","DOI":"10.1016\/j.ad.2012.09.007","article-title":"Drug-induced lupus erythematosus","volume":"105","author":"Pretel M","year":"2014","unstructured":"Pretel M, Marqu\u00e8s L, Espa\u00f1a A. Drug-induced lupus erythematosus. Actas Dermosifiliogr. 2014, 105:18-30. 10.1016\/j.ad.2012.09.007","journal-title":"Actas Dermosifiliogr"},{"key":"ref127","doi-asserted-by":"publisher","DOI":"10.1080\/00015550510026668","article-title":"Lansoprazole-induced subacute cutaneous lupus erythematosus: two cases","volume":"85","author":"Bracke A","year":"2005","unstructured":"Bracke A, Nijsten T, Vandermaesen J, Meuleman L, Lambert J. Lansoprazole-induced subacute cutaneous lupus erythematosus: two cases. Acta Derm Venereol. 2005, 85:353-4. 10.1080\/00015550510026668","journal-title":"Acta Derm Venereol"},{"key":"ref128","doi-asserted-by":"publisher","DOI":"10.1080\/00015550410018361","article-title":"Terbinafine-induced subacute cutaneous lupus erythematosus","volume":"84","author":"McKay DA","year":"2004","unstructured":"McKay DA, Schofield OM, Benton EC. Terbinafine-induced subacute cutaneous lupus erythematosus. Acta Derm Venereol. 2004, 84:472-4. 10.1080\/00015550410018361","journal-title":"Acta Derm Venereol"},{"key":"ref129","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4632.2007.03333.x","article-title":"Leflunomide in subacute cutaneous lupus erythematosus - two sides of a coin","volume":"47","author":"Suess A","year":"2008","unstructured":"Suess A, Sticherling M. Leflunomide in subacute cutaneous lupus erythematosus - two sides of a coin. Int J Dermatol. 2008, 47:83-6. 10.1111\/j.1365-4632.2007.03333.x","journal-title":"Int J Dermatol"},{"key":"ref130","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2007.08.003","article-title":"Drug-induced lupus due to anti-tumor necrosis factor alpha agents","volume":"37","author":"Costa MF","year":"2008","unstructured":"Costa MF, Said NR, Zimmermann B. Drug-induced lupus due to anti-tumor necrosis factor alpha agents. Semin Arthritis Rheum. 2008, 37:381-7. 10.1016\/j.semarthrit.2007.08.003","journal-title":"Semin Arthritis Rheum"},{"key":"ref131","doi-asserted-by":"publisher","DOI":"10.1177\/0961203309103050","article-title":"Chemotherapy-induced subacute lupus erythematosus","volume":"18","author":"Guhl G","year":"2009","unstructured":"Guhl G, Diaz-Ley B, Garc\u00eda-Garc\u00eda C, Fraga J, Garcia-Diez A. Chemotherapy-induced subacute lupus erythematosus. Lupus. 2009, 18:859-60. 10.1177\/0961203309103050","journal-title":"Lupus"},{"key":"ref132","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2012.10969.x","article-title":"Subacute cutaneous lupus erythematosus and its association with drugs: a population-based matched case-control study of 234 patients in Sweden","volume":"167","author":"Gr\u00f6nhagen CM","year":"2012","unstructured":"Gr\u00f6nhagen CM, Fored CM, Linder M, Granath F, Nyberg F. Subacute cutaneous lupus erythematosus and its association with drugs: a population-based matched case-control study of 234 patients in Sweden. Br J Dermatol. 2012, 167:296-305. 10.1111\/j.1365-2133.2012.10969.x","journal-title":"Br J Dermatol"},{"key":"ref133","doi-asserted-by":"publisher","DOI":"10.1007\/s00384-008-0462-8","article-title":"Discoid lupus erythematosus (DLE)-like lesions induced by capecitabine","volume":"23","author":"Merlin F","year":"2008","unstructured":"Merlin F, Prochilo T, Kildani B, Lombardi C, Pasolini G, Bonetti F, Beretta GD. Discoid lupus erythematosus (DLE)-like lesions induced by capecitabine. Int J Colorectal Dis. 2008, 23:715-6. 10.1007\/s00384-008-0462-8","journal-title":"Int J Colorectal Dis"},{"key":"ref134","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kead297","article-title":"Neuropsychiatric lupus in late- and early-onset systemic lupus erythematosus patients: a systematic review and meta-analysis","volume":"63","author":"Pamuk ON","year":"2024","unstructured":"Pamuk ON, Raza AA, Hasni S. Neuropsychiatric lupus in late- and early-onset systemic lupus erythematosus patients: a systematic review and meta-analysis. Rheumatology (Oxford). 2024, 63:8-15. 10.1093\/rheumatology\/kead297","journal-title":"Rheumatology (Oxford)"},{"key":"ref135","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-022-04236-z","article-title":"A cross-sectional study on the association of anxiety and depression with the disease activity of systemic lupus erythematosus","volume":"22","author":"Liao J","year":"2022","unstructured":"Liao J, Kang J, Li F, et al.. A cross-sectional study on the association of anxiety and depression with the disease activity of systemic lupus erythematosus. BMC Psychiatry. 2022, 22:591. 10.1186\/s12888-022-04236-z","journal-title":"BMC Psychiatry"},{"key":"ref136","doi-asserted-by":"publisher","DOI":"10.1002\/acr.23191","article-title":"Medication nonadherence in systemic lupus erythematosus: a systematic review","volume":"69","author":"Mehat P","year":"2017","unstructured":"Mehat P, Atiquzzaman M, Esdaile JM, Avi\u00d1a-Zubieta A, De Vera MA. Medication nonadherence in systemic lupus erythematosus: a systematic review. Arthritis Care Res (Hoboken). 2017, 69:1706-13. 10.1002\/acr.23191","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"ref137","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2013.07.001","article-title":"Adherence to treatment in systemic lupus erythematosus patients","volume":"27","author":"Costedoat-Chalumeau N","year":"2013","unstructured":"Costedoat-Chalumeau N, Pouchot J, Guettrot-Imbert G, et al.. Adherence to treatment in systemic lupus erythematosus patients. Best Pract Res Clin Rheumatol. 2013, 27:329-40. 10.1016\/j.berh.2013.07.001","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"ref138","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keab160","article-title":"Psychosis in systemic lupus erythematosus (SLE): 40-year experience of a specialist centre","volume":"60","author":"Abrol E","year":"2021","unstructured":"Abrol E, Coutinho E, Chou M, et al.. Psychosis in systemic lupus erythematosus (SLE): 40-year experience of a specialist centre. Rheumatology (Oxford). 2021, 60:5620-9. 10.1093\/rheumatology\/keab160","journal-title":"Rheumatology (Oxford)"},{"key":"ref139","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.61.1.104","article-title":"Factors predictive of corticosteroid psychosis in patients with systemic lupus erythematosus","volume":"61","author":"Chau SY","year":"2003","unstructured":"Chau SY, Mok CC. Factors predictive of corticosteroid psychosis in patients with systemic lupus erythematosus. Neurology. 2003, 61:104-7. 10.1212\/wnl.61.1.104","journal-title":"Neurology"},{"key":"ref140","doi-asserted-by":"publisher","DOI":"10.1093\/ptj\/pzad147","article-title":"A call to action for mental and behavioral health stakeholders: use physical therapists to close the gap in depression care","volume":"104","author":"Tatta J","year":"2024","unstructured":"Tatta J. A call to action for mental and behavioral health stakeholders: use physical therapists to close the gap in depression care. Phys Ther. 2024, 104:147. 10.1093\/ptj\/pzad147","journal-title":"Phys Ther"},{"key":"ref141","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003585.pub3","article-title":"Occupational therapy for adults with problems in activities of daily living after stroke","volume":"7","author":"Legg LA","year":"2017","unstructured":"Legg LA, Lewis SR, Schofield-Robinson OJ, Drummond A, Langhorne P. Occupational therapy for adults with problems in activities of daily living after stroke. Cochrane Database Syst Rev. 2017, 7:003585. 10.1002\/14651858.CD003585.pub3","journal-title":"Cochrane Database Syst Rev"},{"key":"ref142","doi-asserted-by":"publisher","DOI":"10.3390\/nursrep12010022","article-title":"The effectiveness of psychoeducational interventions in adolescents\u2019 anxiety: a systematic review protocol","volume":"12","author":"Morgado T","year":"2022","unstructured":"Morgado T, Lopes V, Carvalho D, Santos E. The effectiveness of psychoeducational interventions in adolescents\u2019 anxiety: a systematic review protocol. Nurs Rep. 2022, 12:217-25. 10.3390\/nursrep12010022","journal-title":"Nurs Rep"},{"key":"ref143","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.057885","article-title":"Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system","volume":"66","author":"Tokunaga M","year":"2007","unstructured":"Tokunaga M, Saito K, Kawabata D, et al.. Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system. Ann Rheum Dis. 2007, 66:470-5. 10.1136\/ard.2006.057885","journal-title":"Ann Rheum Dis"},{"key":"ref144","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2022-000835","article-title":"Clinical associations of cognitive dysfunction in systemic lupus erythematosus","volume":"10","author":"Raghunath S","year":"2023","unstructured":"Raghunath S, Glikmann-Johnston Y, Golder V, Kandane-Rathnayake R, Morand EF, Stout JC, Hoi A. Clinical associations of cognitive dysfunction in systemic lupus erythematosus. Lupus Sci Med. 2023, 10:000835. 10.1136\/lupus-2022-000835","journal-title":"Lupus Sci Med"},{"key":"ref145","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000180938.69146.5e","article-title":"Results of intervention for lupus patients with self-perceived cognitive difficulties","volume":"65","author":"Harrison MJ","year":"2005","unstructured":"Harrison MJ, Morris KA, Horton R, et al.. Results of intervention for lupus patients with self-perceived cognitive difficulties. Neurology. 2005, 65:1325-7. 10.1212\/01.wnl.0000180938.69146.5e","journal-title":"Neurology"},{"key":"ref146","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2011.02.005","article-title":"Memantine in systemic lupus erythematosus: a randomized, double-blind placebo-controlled trial","volume":"41","author":"Petri M","year":"2011","unstructured":"Petri M, Naqibuddin M, Sampedro M, Omdal R, Carson KA. Memantine in systemic lupus erythematosus: a randomized, double-blind placebo-controlled trial. Semin Arthritis Rheum. 2011, 41:194-202. 10.1016\/j.semarthrit.2011.02.005","journal-title":"Semin Arthritis Rheum"},{"key":"ref147","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-201089","article-title":"Seizure disorders in systemic lupus erythematosus results from an international, prospective, inception cohort study","volume":"71","author":"Hanly JG","year":"2012","unstructured":"Hanly JG, Urowitz MB, Su L, et al.. Seizure disorders in systemic lupus erythematosus results from an international, prospective, inception cohort study. Ann Rheum Dis. 2012, 71:1502-9. 10.1136\/annrheumdis-2011-201089","journal-title":"Ann Rheum Dis"},{"key":"ref148","doi-asserted-by":"publisher","DOI":"10.1177\/0961203316688784","article-title":"Stroke in systemic lupus erythematosus and antiphospholipid syndrome: risk factors, clinical manifestations, neuroimaging, and treatment","volume":"26","author":"de Amorim LC","year":"2017","unstructured":"de Amorim LC, Maia FM, Rodrigues CE. Stroke in systemic lupus erythematosus and antiphospholipid syndrome: risk factors, clinical manifestations, neuroimaging, and treatment. Lupus. 2017, 26:529-36. 10.1177\/0961203316688784","journal-title":"Lupus"},{"key":"ref149","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.978910","article-title":"Exploring the risk factors for ischemic cerebrovascular disease in systemic lupus erythematosus: a single-center case-control study","volume":"13","author":"Su L","year":"2022","unstructured":"Su L, Qi Z, Guan S, Wei L, Zhao Y. Exploring the risk factors for ischemic cerebrovascular disease in systemic lupus erythematosus: a single-center case-control study. Front Immunol. 2022, 13:978910. 10.3389\/fimmu.2022.978910","journal-title":"Front Immunol"},{"key":"ref150","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1997.tb48400.x","article-title":"Antiphospholipid antibodies and cerebral lupus","volume":"823","author":"Harris EN","year":"1997","unstructured":"Harris EN, Pierangeli S. Antiphospholipid antibodies and cerebral lupus. Ann N Y Acad Sci. 1997, 823:270-8. 10.1111\/j.1749-6632.1997.tb48400.x","journal-title":"Ann N Y Acad Sci"},{"key":"ref151","doi-asserted-by":"publisher","DOI":"10.1177\/0961203314552115","article-title":"Clinical and electrophysiological characteristics of symmetric polyneuropathy in a cohort of systemic lupus erythematosus patients","volume":"24","author":"Jasmin R","year":"2015","unstructured":"Jasmin R, Sockalingam S, Ramanaidu LP, Goh KJ. Clinical and electrophysiological characteristics of symmetric polyneuropathy in a cohort of systemic lupus erythematosus patients. Lupus. 2015, 24:248-55. 10.1177\/0961203314552115","journal-title":"Lupus"},{"key":"ref152","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2021-000521","article-title":"Peripheral neuropathy in systemic lupus erythematosus: what can neuromuscular ultrasonography (NMUS) tell us? A cross-sectional study","volume":"8","author":"Mahran SA","year":"2021","unstructured":"Mahran SA, Galluccio F, Khedr TM, et al.. Peripheral neuropathy in systemic lupus erythematosus: what can neuromuscular ultrasonography (NMUS) tell us? A cross-sectional study. Lupus Sci Med. 2021, 8:000521. 10.1136\/lupus-2021-000521","journal-title":"Lupus Sci Med"},{"key":"ref153","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000000625","article-title":"Peripheral neuropathies due to systemic lupus erythematosus in China","volume":"94","author":"Xianbin W","year":"2015","unstructured":"Xianbin W, Mingyu W, Dong X, Huiying L, Yan X, Fengchun Z, Xiaofeng Z. Peripheral neuropathies due to systemic lupus erythematosus in China. Medicine (Baltimore). 2015, 94:625. 10.1097\/MD.0000000000000625","journal-title":"Medicine (Baltimore)"},{"key":"ref154","doi-asserted-by":"publisher","DOI":"10.1016\/j.mjafi.2023.02.007","article-title":"Guillain-Barre syndrome as the initial presentation of systemic lupus erythematosus: case report with a systematic and literature review","volume":"79","author":"Bhoi SK","year":"2023","unstructured":"Bhoi SK, Jha M, Jaiswal B. Guillain-Barre syndrome as the initial presentation of systemic lupus erythematosus: case report with a systematic and literature review. Med J Armed Forces India. 2023, 79:360-4. 10.1016\/j.mjafi.2023.02.007","journal-title":"Med J Armed Forces India"},{"key":"ref155","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2023.101933","article-title":"Neural circuit changes in neurological disorders: evidence from in vivo two-photon imaging","volume":"87","author":"Xiong H","year":"2023","unstructured":"Xiong H, Tang F, Guo Y, Xu R, Lei P. Neural circuit changes in neurological disorders: evidence from in vivo two-photon imaging. Ageing Res Rev. 2023, 87:101933. 10.1016\/j.arr.2023.101933","journal-title":"Ageing Res Rev"},{"key":"ref156","doi-asserted-by":"publisher","DOI":"10.4081\/reumatismo.2017.1007","article-title":"Demyelinating syndrome in SLE: review of different disease subtypes and report of a case series","volume":"69","author":"Chessa E","year":"2017","unstructured":"Chessa E, Piga M, Floris A, Mathieu A, Cauli A. Demyelinating syndrome in SLE: review of different disease subtypes and report of a case series. Reumatismo. 2017, 69:175-83. 10.4081\/reumatismo.2017.1007","journal-title":"Reumatismo"},{"key":"ref157","doi-asserted-by":"publisher","DOI":"10.1177\/1352458508096878","article-title":"Differential diagnosis of suspected multiple sclerosis: a consensus approach","volume":"14","author":"Miller DH","year":"2008","unstructured":"Miller DH, Weinshenker BG, Filippi M, et al.. Differential diagnosis of suspected multiple sclerosis: a consensus approach. Mult Scler. 2008, 14:1157-74. 10.1177\/1352458508096878","journal-title":"Mult Scler"},{"key":"ref158","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2013.07.010","article-title":"Demyelinating disease in SLE: is it multiple sclerosis or lupus?","volume":"27","author":"Magro Checa C","year":"2013","unstructured":"Magro Checa C, Cohen D, Bollen EL, van Buchem MA, Huizinga TW, Steup-Beekman GM. Demyelinating disease in SLE: is it multiple sclerosis or lupus?. Best Pract Res Clin Rheumatol. 2013, 27:405-24. 10.1016\/j.berh.2013.07.010","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"ref159","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.889613","article-title":"Demyelinating syndromes in systemic lupus erythematosus: data from the \u201cAttikon\u201d lupus cohort","volume":"13","author":"Nikolopoulos D","year":"2022","unstructured":"Nikolopoulos D, Kitsos D, Papathanasiou M, et al.. Demyelinating syndromes in systemic lupus erythematosus: data from the \u201cAttikon\u201d lupus cohort. Front Neurol. 2022, 13:889613. 10.3389\/fneur.2022.889613","journal-title":"Front Neurol"},{"key":"ref160","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200110)44:10<2331::aid-art395>3.0.co;2-i","article-title":"Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus","volume":"44","author":"Esdaile JM","year":"2001","unstructured":"Esdaile JM, Abrahamowicz M, Grodzicky T, et al.. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum. 2001, 44:2331-7. 10.1002\/1529-0131(200110)44:10&lt;2331::aid-art395&gt;3.0.co;2-i","journal-title":"Arthritis Rheum"},{"key":"ref161","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(199801)41:1<41::AID-ART6>3.0.CO;2-7","article-title":"Magnetic resonance imaging abnormalities and cognitive deficits in systemic lupus erythematosus patients without overt central nervous system disease","volume":"41","author":"Kozora E","year":"1998","unstructured":"Kozora E, West SG, Kotzin BL, Julian L, Porter S, Bigler E. Magnetic resonance imaging abnormalities and cognitive deficits in systemic lupus erythematosus patients without overt central nervous system disease. Arthritis Rheum. 1998, 41:41-7. 10.1002\/1529-0131(199801)41:1&lt;41::AID-ART6&gt;3.0.CO;2-7","journal-title":"Arthritis Rheum"},{"key":"ref162","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.38.785","article-title":"Asymptomatic cerebrovascular lesions detected by magnetic resonance imaging in patients with systemic lupus erythematosus lacking a history of neuropsychiatric events","volume":"38","author":"Nomura K","year":"1999","unstructured":"Nomura K, Yamano S, Ikeda Y, et al.. Asymptomatic cerebrovascular lesions detected by magnetic resonance imaging in patients with systemic lupus erythematosus lacking a history of neuropsychiatric events. Intern Med. 1999, 38:785-95. 10.2169\/internalmedicine.38.785","journal-title":"Intern Med"},{"key":"ref163","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(199910)42:10<2026::AID-ANR2>3.0.CO;2-J","article-title":"Neuroimaging in neuropsychiatric systemic lupus erythematosus","volume":"42","author":"Sibbitt WL Jr","year":"1999","unstructured":"Sibbitt WL Jr, Sibbitt RR, Brooks WM. Neuroimaging in neuropsychiatric systemic lupus erythematosus. Arthritis Rheum. 1999, 42:2026-38. 10.1002\/1529-0131(199910)42:10&lt;2026::AID-ANR2&gt;3.0.CO;2-J","journal-title":"Arthritis Rheum"},{"key":"ref164","doi-asserted-by":"publisher","DOI":"10.1007\/s004150170138","article-title":"Neuropsychological dysfunction in systemic lupus erythematosus is not associated with changes in cerebral blood flow","volume":"248","author":"Waterloo K","year":"2001","unstructured":"Waterloo K, Omdal R, Sj\u00f6holm H, et al.. Neuropsychological dysfunction in systemic lupus erythematosus is not associated with changes in cerebral blood flow. J Neurol. 2001, 248:595-602. 10.1007\/s004150170138","journal-title":"J Neurol"},{"key":"ref165","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.140027","article-title":"Cluster analysis of an array of autoantibodies in neuropsychiatric systemic lupus erythematosus","volume":"41","author":"Zirkzee EJ","year":"2014","unstructured":"Zirkzee EJ, Magro Checa C, Sohrabian A, Steup-Beekman GM. Cluster analysis of an array of autoantibodies in neuropsychiatric systemic lupus erythematosus. J Rheumatol. 2014, 41:1720-1. 10.3899\/jrheum.140027","journal-title":"J Rheumatol"},{"key":"ref166","doi-asserted-by":"publisher","DOI":"10.1002\/art.22540","article-title":"Devic's syndrome in a woman with systemic lupus erythematosus: diagnostic and therapeutic implications of testing for the neuromyelitis optica IgG autoantibody","volume":"57","author":"Birnbaum J","year":"2007","unstructured":"Birnbaum J, Kerr D. Devic's syndrome in a woman with systemic lupus erythematosus: diagnostic and therapeutic implications of testing for the neuromyelitis optica IgG autoantibody. Arthritis Rheum. 2007, 57:347-51. 10.1002\/art.22540","journal-title":"Arthritis Rheum"},{"key":"ref167","doi-asserted-by":"publisher","DOI":"10.1002\/art.24937","article-title":"Distinct subtypes of myelitis in systemic lupus erythematosus","volume":"60","author":"Birnbaum J","year":"2009","unstructured":"Birnbaum J, Petri M, Thompson R, Izbudak I, Kerr D. Distinct subtypes of myelitis in systemic lupus erythematosus. Arthritis Rheum. 2009, 60:3378-87. 10.1002\/art.24937","journal-title":"Arthritis Rheum"},{"key":"ref168","doi-asserted-by":"publisher","DOI":"10.1159\/000121423","article-title":"Clinical description of seizures in patients with systemic lupus erythematosus","volume":"59","author":"Gonz\u00e1lez-Duarte A","year":"2008","unstructured":"Gonz\u00e1lez-Duarte A, Cant\u00fa-Brito CG, Ruano-Calder\u00f3n L, Garc\u00eda-Ramos G. Clinical description of seizures in patients with systemic lupus erythematosus. Eur Neurol. 2008, 59:320-3. 10.1159\/000121423","journal-title":"Eur Neurol"},{"key":"ref169","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000144178.32208.4f","article-title":"Epileptic seizures in systemic lupus erythematosus","volume":"63","author":"Appenzeller S","year":"2004","unstructured":"Appenzeller S, Cendes F, Costallat LT. Epileptic seizures in systemic lupus erythematosus. Neurology. 2004, 63:1808-12. 10.1212\/01.wnl.0000144178.32208.4f","journal-title":"Neurology"},{"key":"ref170","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2014.15","article-title":"Diagnosis and management of neuropsychiatric SLE","volume":"10","author":"Hanly JG","year":"2014","unstructured":"Hanly JG. Diagnosis and management of neuropsychiatric SLE. Nat Rev Rheumatol. 2014, 10:338-47. 10.1038\/nrrheum.2014.15","journal-title":"Nat Rev Rheumatol"},{"key":"ref171","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.120545","article-title":"Prospective study of clinical phenotypes in neuropsychiatric systemic lupus erythematosus; multidisciplinary approach to diagnosis and therapy","volume":"39","author":"Zirkzee EJ","year":"2012","unstructured":"Zirkzee EJ, Steup-Beekman GM, van der Mast RC, et al.. Prospective study of clinical phenotypes in neuropsychiatric systemic lupus erythematosus; multidisciplinary approach to diagnosis and therapy. J Rheumatol. 2012, 39:2118-26. 10.3899\/jrheum.120545","journal-title":"J Rheumatol"},{"key":"ref172","doi-asserted-by":"publisher","DOI":"10.1191\/0961203303lu251oa","article-title":"Neuropsychiatric lupus favourable response to low dose i.v. cyclophosphamide and prednisolone (pilot study)","volume":"12","author":"Stojanovich L","year":"2003","unstructured":"Stojanovich L, Stojanovich R, Kostich V, Dzjolich E. Neuropsychiatric lupus favourable response to low dose i.v. cyclophosphamide and prednisolone (pilot study). Lupus. 2003, 12:3-7. 10.1191\/0961203303lu251oa","journal-title":"Lupus"},{"key":"ref173","doi-asserted-by":"publisher","DOI":"10.1046\/j.1526-0968.2003.00032.x","article-title":"The role of plasmapheresis in the treatment of severe central nervous system neuropsychiatric systemic lupus erythematosus","volume":"7","author":"Neuwelt CM","year":"2003","unstructured":"Neuwelt CM. The role of plasmapheresis in the treatment of severe central nervous system neuropsychiatric systemic lupus erythematosus. Ther Apher Dial. 2003, 7:173-82. 10.1046\/j.1526-0968.2003.00032.x","journal-title":"Ther Apher Dial"},{"key":"ref174","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-004-1046-9","article-title":"Treatment of acute neuropsychiatric lupus with intravenous immunoglobulin (IVIG): a case report and review of the literature","volume":"24","author":"Milstone AM","year":"2005","unstructured":"Milstone AM, Meyers K, Elia J. Treatment of acute neuropsychiatric lupus with intravenous immunoglobulin (IVIG): a case report and review of the literature. Clin Rheumatol. 2005, 24:394-7. 10.1007\/s10067-004-1046-9","journal-title":"Clin Rheumatol"},{"key":"ref175","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2005.08.008","article-title":"Chronic inflammatory demyelinating polyneuropathy in patients with systemic lupus erythematosus: prognosis and outcome","volume":"35","author":"Vina ER","year":"2005","unstructured":"Vina ER, Fang AJ, Wallace DJ, Weisman MH. Chronic inflammatory demyelinating polyneuropathy in patients with systemic lupus erythematosus: prognosis and outcome. Semin Arthritis Rheum. 2005, 35:175-84. 10.1016\/j.semarthrit.2005.08.008","journal-title":"Semin Arthritis Rheum"},{"key":"ref176","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.025528","article-title":"Controlled clinical trial of IV cyclophosphamide versus IV methylprednisolone in severe neurological manifestations in systemic lupus erythematosus","volume":"64","author":"Barile-Fabris L","year":"2005","unstructured":"Barile-Fabris L, Ariza-Andraca R, Olgu\u00edn-Ortega L, et al.. Controlled clinical trial of IV cyclophosphamide versus IV methylprednisolone in severe neurological manifestations in systemic lupus erythematosus. Ann Rheum Dis. 2005, 64:620-5. 10.1136\/ard.2004.025528","journal-title":"Ann Rheum Dis"},{"key":"ref177","doi-asserted-by":"publisher","DOI":"10.1016\/s0049-0172(99)80029-8","article-title":"Clinical study and follow-up of 100 patients with the antiphospholipid syndrome","volume":"29","author":"Mu\u00f1oz-Rodriguez FJ","year":"1999","unstructured":"Mu\u00f1oz-Rodriguez FJ, Font J, Cervera R, et al.. Clinical study and follow-up of 100 patients with the antiphospholipid syndrome. Semin Arthritis Rheum. 1999, 29:182-90. 10.1016\/s0049-0172(99)80029-8","journal-title":"Semin Arthritis Rheum"},{"key":"ref178","doi-asserted-by":"publisher","DOI":"10.1002\/art.27289","article-title":"The protective effect of antimalarial drugs on thrombovascular events in systemic lupus erythematosus","volume":"62","author":"Jung H","year":"2010","unstructured":"Jung H, Bobba R, Su J, et al.. The protective effect of antimalarial drugs on thrombovascular events in systemic lupus erythematosus. Arthritis Rheum. 2010, 62:863-8. 10.1002\/art.27289","journal-title":"Arthritis Rheum"},{"key":"ref179","doi-asserted-by":"publisher","DOI":"10.1053\/berh.2001.0223","article-title":"Diagnosis and management of patients with neuropsychiatric systemic lupus erythematosus (NPSLE)","volume":"16","author":"Hermosillo-Romo D","year":"2002","unstructured":"Hermosillo-Romo D, Brey RL. Diagnosis and management of patients with neuropsychiatric systemic lupus erythematosus (NPSLE). Best Pract Res Clin Rheumatol. 2002, 16:229-44. 10.1053\/berh.2001.0223","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"ref180","doi-asserted-by":"publisher","DOI":"10.1002\/art.21039","article-title":"Systemic lupus erythematosus in three ethnic groups: XVI. Association of hydroxychloroquine use with reduced risk of damage accrual","volume":"52","author":"Fessler BJ","year":"2005","unstructured":"Fessler BJ, Alarc\u00f3n GS, McGwin G Jr, et al.. Systemic lupus erythematosus in three ethnic groups: XVI. Association of hydroxychloroquine use with reduced risk of damage accrual. Arthritis Rheum. 2005, 52:1473-80. 10.1002\/art.21039","journal-title":"Arthritis Rheum"},{"key":"ref181","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-010-0141-y","article-title":"Use of hydroxychloroquine to prevent thrombosis in systemic lupus erythematosus and in antiphospholipid antibody-positive patients","volume":"13","author":"Petri M","year":"2011","unstructured":"Petri M. Use of hydroxychloroquine to prevent thrombosis in systemic lupus erythematosus and in antiphospholipid antibody-positive patients. Curr Rheumatol Rep. 2011, 13:77-80. 10.1007\/s11926-010-0141-y","journal-title":"Curr Rheumatol Rep"},{"key":"ref182","doi-asserted-by":"publisher","DOI":"10.1016\/s0163-7258(02)00297-8","article-title":"Mechanisms involved in the side effects of glucocorticoids","volume":"96","author":"Sch\u00e4cke H","year":"2002","unstructured":"Sch\u00e4cke H, D\u00f6cke WD, Asadullah K. Mechanisms involved in the side effects of glucocorticoids. Pharmacol Ther. 2002, 96:23-43. 10.1016\/s0163-7258(02)00297-8","journal-title":"Pharmacol Ther"},{"key":"ref183","doi-asserted-by":"publisher","DOI":"10.1136\/ard.61.8.718","article-title":"Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: current questions and tentative answers in rheumatology","volume":"61","author":"Buttgereit F","year":"2002","unstructured":"Buttgereit F, da Silva JA, Boers M, et al.. Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: current questions and tentative answers in rheumatology. Ann Rheum Dis. 2002, 61:718-22. 10.1136\/ard.61.8.718","journal-title":"Ann Rheum Dis"},{"key":"ref184","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200363030-00002","article-title":"Treatment of lupus nephritis","volume":"63","author":"Hejaili FF","year":"2003","unstructured":"Hejaili FF, Moist LM, Clark WF. Treatment of lupus nephritis. Drugs. 2003, 63:257-74. 10.2165\/00003495-200363030-00002","journal-title":"Drugs"},{"key":"ref185","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.102533","article-title":"The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide","volume":"69","author":"Houssiau FA","year":"2010","unstructured":"Houssiau FA, Vasconcelos C, D'Cruz D, et al.. The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide. Ann Rheum Dis. 2010, 69:61-4. 10.1136\/ard.2008.102533","journal-title":"Ann Rheum Dis"},{"key":"ref186","article-title":"Increased incidence of cervical intraepithelial neoplasia in women with systemic lupus erythematosus treated with intravenous cyclophosphamide","volume":"31","author":"Ognenovski VM","year":"2004","unstructured":"Ognenovski VM, Marder W, Somers EC, Johnston CM, Farrehi JG, Selvaggi SM, McCune WJ. Increased incidence of cervical intraepithelial neoplasia in women with systemic lupus erythematosus treated with intravenous cyclophosphamide. J Rheumatol. 2004, 31:1763-7.","journal-title":"J Rheumatol"},{"key":"ref187","doi-asserted-by":"publisher","DOI":"10.3949\/ccjm.82a.14106","article-title":"Should thiopurine methyltransferase (TPMT) activity be determined be-fore prescribing azathioprine, mercaptopurine, or thioguanine?","volume":"82","author":"DiPiero J","year":"2015","unstructured":"DiPiero J, Teng K, Hicks JK. Should thiopurine methyltransferase (TPMT) activity be determined be-fore prescribing azathioprine, mercaptopurine, or thioguanine?. Cleve Clin J Med. 2015, 82:409-413. 10.3949\/ccjm.82a.14106","journal-title":"Cleve Clin J Med"},{"key":"ref188","doi-asserted-by":"publisher","DOI":"10.1007\/BF01419725","article-title":"Predictors of flares and long-term outcome of systemic lu-pus erythematosus during combined treatment with azathioprine and low-dose prednisolone","volume":"16","author":"Oelzner P","year":"1996","unstructured":"Oelzner P, Abendroth K, Hein G, Stein G. Predictors of flares and long-term outcome of systemic lu-pus erythematosus during combined treatment with azathioprine and low-dose prednisolone. Rheu-matol Int. 1996, 16:133-139. 10.1007\/BF01419725","journal-title":"Rheu-matol Int"},{"key":"ref189","doi-asserted-by":"publisher","DOI":"10.1191\/0961203305lu2109oa","article-title":"Mechanisms of action of mycophenolate mofetil","volume":"14","author":"Allison AC","year":"2005","unstructured":"Allison AC. Mechanisms of action of mycophenolate mofetil. Lupus. 2005, 14:2-8. 10.1191\/0961203305lu2109oa","journal-title":"Lupus"},{"key":"ref190","article-title":"Mycophenolate mofetil in systemic lupus erythematosus: efficacy and tolerability in 86 patients","volume":"32","author":"Pisoni CN","year":"2005","unstructured":"Pisoni CN, Sanchez FJ, Karim Y, et al.. Mycophenolate mofetil in systemic lupus erythematosus: efficacy and tolerability in 86 patients. J Rheumatol. 2005, 32:1047-52.","journal-title":"J Rheumatol"},{"key":"ref191","doi-asserted-by":"publisher","DOI":"10.1177\/0961203307085671","article-title":"Clinical features and outcome of neuropsychiatric lupus in Chinese: analysis of 240 hospitalized patients","volume":"17","author":"Zhou HQ","year":"2008","unstructured":"Zhou HQ, Zhang FC, Tian XP, et al.. Clinical features and outcome of neuropsychiatric lupus in Chinese: analysis of 240 hospitalized patients. Lupus. 2008, 17:93-9. 10.1177\/0961203307085671","journal-title":"Lupus"},{"key":"ref192","doi-asserted-by":"publisher","DOI":"10.1007\/s12013-014-0010-9","article-title":"Impact analysis of autoantibody level and NR2 antibody level in neuropsychiatric SLE treated by methylprednisolone combined with MTX and DXM intrathecal injection","volume":"70","author":"Wang J","year":"2014","unstructured":"Wang J, Zhao Y, Zhang J, Lei H, Zhu G, Fu B. Impact analysis of autoantibody level and NR2 antibody level in neuropsychiatric SLE treated by methylprednisolone combined with MTX and DXM intrathecal injection. Cell Biochem Biophys. 2014, 70:1005-9. 10.1007\/s12013-014-0010-9","journal-title":"Cell Biochem Biophys"},{"key":"ref193","doi-asserted-by":"publisher","DOI":"10.1046\/j.1525-1594.2000.06623.x","article-title":"Cyclosporin A and therapeutic plasma exchange in the treatment of severe systemic lupus erythematosus","volume":"24","author":"Bambauer R","year":"2000","unstructured":"Bambauer R, Schwarze U, Schiel R. Cyclosporin A and therapeutic plasma exchange in the treatment of severe systemic lupus erythematosus. Artif Organs. 2000, 24:852-6. 10.1046\/j.1525-1594.2000.06623.x","journal-title":"Artif Organs"},{"key":"ref194","doi-asserted-by":"publisher","DOI":"10.3892\/etm.2014.1669","article-title":"Calcineurin inhibitors may be a reasonable alternative to cyclophosphamide in the induction treatment of active lupus nephritis: A systematic review and meta-analysis","volume":"7","author":"Yang M","year":"2014","unstructured":"Yang M, Li M, He W, Wang B, Gu Y. Calcineurin inhibitors may be a reasonable alternative to cyclophosphamide in the induction treatment of active lupus nephritis: A systematic review and meta-analysis. Exp Ther Med. 2014, 7:1663-70. 10.3892\/etm.2014.1669","journal-title":"Exp Ther Med"},{"key":"ref195","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2007.06.151","article-title":"Mechanisms of killing by anti-CD20 monoclonal antibodies","volume":"44","author":"Glennie MJ","year":"2007","unstructured":"Glennie MJ, French RR, Cragg MS, Taylor RP. Mechanisms of killing by anti-CD20 monoclonal antibodies. Mol Immunol. 2007, 44:3823-37. 10.1016\/j.molimm.2007.06.151","journal-title":"Mol Immunol"},{"key":"ref196","article-title":"Treatment with intravenous immunoglobulins in systemic lupus erythematosus: a series of 52 patients from a single centre","volume":"32","author":"Camara I","year":"2014","unstructured":"Camara I, Sciascia S, Simoes J, et al.. Treatment with intravenous immunoglobulins in systemic lupus erythematosus: a series of 52 patients from a single centre. Clin Exp Rheumatol. 2014, 32:41-7.","journal-title":"Clin Exp Rheumatol"},{"key":"ref197","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60503-1","article-title":"Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials","volume":"373","author":"Baigent C","year":"2009","unstructured":"Baigent C, Blackwell L, Collins R, et al.. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009, 373:1849-60. 10.1016\/S0140-6736(09)60503-1","journal-title":"Lancet"},{"key":"ref198","doi-asserted-by":"publisher","DOI":"10.1002\/art.24232","article-title":"Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies","volume":"61","author":"Tektonidou MG","year":"2009","unstructured":"Tektonidou MG, Laskari K, Panagiotakos DB, Moutsopoulos HM. Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies. Arthritis Rheum. 2009, 61:29-36. 10.1002\/art.24232","journal-title":"Arthritis Rheum"},{"key":"ref199","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.107.189063","article-title":"Update to the AHA\/ASA recommendations for the prevention of stroke in patients with stroke and transient ischemic attack","volume":"39","author":"Adams RJ","year":"2008","unstructured":"Adams RJ, Albers G, Alberts MJ, et al.. Update to the AHA\/ASA recommendations for the prevention of stroke in patients with stroke and transient ischemic attack. Stroke. 2008, 39:1647-52. 10.1161\/STROKEAHA.107.189063","journal-title":"Stroke"},{"key":"ref200","doi-asserted-by":"publisher","DOI":"10.1177\/0961203310395803","article-title":"Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: report of a task force at the 13th International Congress on antiphospholipid antibodies","volume":"20","author":"Ruiz-Irastorza G","year":"2011","unstructured":"Ruiz-Irastorza G, Cuadrado MJ, Ruiz-Arruza I, et al.. Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: report of a task force at the 13th International Congress on antiphospholipid antibodies. Lupus. 2011, 20:206-18. 10.1177\/0961203310395803","journal-title":"Lupus"},{"key":"ref201","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ket313","article-title":"Low-dose aspirin vs low-dose aspirin plus low-intensity warfarin in thromboprophylaxis: a prospective, multicentre, randomized, open, controlled trial in patients positive for antiphospholipid antibodies (ALIWAPAS)","volume":"53","author":"Cuadrado MJ","year":"2014","unstructured":"Cuadrado MJ, Bertolaccini ML, Seed PT, et al.. Low-dose aspirin vs low-dose aspirin plus low-intensity warfarin in thromboprophylaxis: a prospective, multicentre, randomized, open, controlled trial in patients positive for antiphospholipid antibodies (ALIWAPAS). Rheumatology (Oxford). 2014, 53:275-84. 10.1093\/rheumatology\/ket313","journal-title":"Rheumatology (Oxford)"},{"key":"ref202","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keae216","article-title":"Patients with NPSLE experience poorer HRQoL and more fatigue than SLE patients with no neuropsychiatric involvement, irrespective of neuropsychiatric activity","volume":"63","author":"Nikolopoulos D","year":"2024","unstructured":"Nikolopoulos D, Cetrez N, Lindblom J, Palazzo L, Enman Y, Parodis I. Patients with NPSLE experience poorer HRQoL and more fatigue than SLE patients with no neuropsychiatric involvement, irrespective of neuropsychiatric activity. Rheumatology (Oxford). 2024, 63:2494-502. 10.1093\/rheumatology\/keae216","journal-title":"Rheumatology (Oxford)"},{"key":"ref203","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/41.11.1308","article-title":"Outcome of neuropsychiatric systemic lupus erythematosus within a defined Swedish population: increased morbidity but low mortality","volume":"41","author":"J\u00f6nsen A","year":"2002","unstructured":"J\u00f6nsen A, Bengtsson AA, Nived O, Ryberg B, Sturfelt G. Outcome of neuropsychiatric systemic lupus erythematosus within a defined Swedish population: increased morbidity but low mortality. Rheumatology (Oxford). 2002, 41:1308-12. 10.1093\/rheumatology\/41.11.1308","journal-title":"Rheumatology (Oxford)"},{"key":"ref204","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ken477","article-title":"Employment and work disability in systemic lupus erythematosus: a systematic review","volume":"48","author":"Baker K","year":"2009","unstructured":"Baker K, Pope J. Employment and work disability in systemic lupus erythematosus: a systematic review. Rheumatology (Oxford). 2009, 48:281-4. 10.1093\/rheumatology\/ken477","journal-title":"Rheumatology (Oxford)"},{"key":"ref205","doi-asserted-by":"publisher","DOI":"10.1177\/09612033211031008","article-title":"Cognitive impairment in systemic lupus erythematosus is negatively related to social role participation and quality of life: A systematic review","volume":"30","author":"Mendelsohn S","year":"2021","unstructured":"Mendelsohn S, Khoja L, Alfred S, et al.. Cognitive impairment in systemic lupus erythematosus is negatively related to social role participation and quality of life: A systematic review. Lupus. 2021, 30:1617-30. 10.1177\/09612033211031008","journal-title":"Lupus"},{"key":"ref206","doi-asserted-by":"publisher","DOI":"10.1177\/0961203318772021","article-title":"Prevalence, risk factors, and impact on mortality of neuropsychiatric lupus: a prospective, single-center study","volume":"27","author":"Ahn GY","year":"2018","unstructured":"Ahn GY, Kim D, Won S, et al.. Prevalence, risk factors, and impact on mortality of neuropsychiatric lupus: a prospective, single-center study. Lupus. 2018, 27:1338-47. 10.1177\/0961203318772021","journal-title":"Lupus"},{"key":"ref207","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keae119","article-title":"Therapeutic strategies and outcomes in neuropsychiatric systemic lupus erythematosus: an international multicentre retrospective study","volume":"63","author":"Bortoluzzi A","year":"2024","unstructured":"Bortoluzzi A, Fanouriakis A, Silvagni E, et al.. Therapeutic strategies and outcomes in neuropsychiatric systemic lupus erythematosus: an international multicentre retrospective study. Rheumatology (Oxford). 2024, 63:2711-20. 10.1093\/rheumatology\/keae119","journal-title":"Rheumatology (Oxford)"},{"key":"ref208","doi-asserted-by":"publisher","DOI":"10.1177\/09612033221074580","article-title":"The association between lupus serology and disease outcomes: a systematic literature review to inform the treat-to-target approach in systemic lupus erythematosus","volume":"31","author":"Kostopoulou M","year":"2022","unstructured":"Kostopoulou M, Ugarte-Gil MF, Pons-Estel B, van Vollenhoven RF, Bertsias G. The association between lupus serology and disease outcomes: a systematic literature review to inform the treat-to-target approach in systemic lupus erythematosus. Lupus. 2022, 31:307-18. 10.1177\/09612033221074580","journal-title":"Lupus"},{"key":"ref209","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-024-07056-6","article-title":"Correlation between neuropsychiatric systemic lupus erythematosus and immunological markers: a real-world retrospective study","volume":"43","author":"Jiang Y","year":"2024","unstructured":"Jiang Y, Yuan F, Xu X, et al.. Correlation between neuropsychiatric systemic lupus erythematosus and immunological markers: a real-world retrospective study. Clin Rheumatol. 2024, 43:2833-42. 10.1007\/s10067-024-07056-6","journal-title":"Clin Rheumatol"},{"key":"ref210","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.12213","article-title":"Neuropsychiatric manifestations in a consecutive cohort of systemic lupus erythematosus; a single center study","volume":"16","author":"Abdul-Sattar AB","year":"2013","unstructured":"Abdul-Sattar AB, Goda T, Negm MG. Neuropsychiatric manifestations in a consecutive cohort of systemic lupus erythematosus; a single center study. Int J Rheum Dis. 2013, 16:715-23. 10.1111\/1756-185X.12213","journal-title":"Int J Rheum Dis"},{"key":"ref211","doi-asserted-by":"publisher","DOI":"10.1177\/0961203320938453","article-title":"Low C4 as a risk factor for severe neuropsychiatric flare in patients with systemic lupus erythematosus","volume":"29","author":"Aso K","year":"2020","unstructured":"Aso K, Kono M, Kono M, et al.. Low C4 as a risk factor for severe neuropsychiatric flare in patients with systemic lupus erythematosus. Lupus. 2020, 29:1238-47. 10.1177\/0961203320938453","journal-title":"Lupus"},{"key":"ref212","doi-asserted-by":"publisher","DOI":"10.1093\/mr\/roac076","article-title":"Efficacy of belimumab in patients with systemic lupus erythematosus from North East Asia: Results of exploratory subgroup analyses","volume":"33","author":"Zheng J","year":"2023","unstructured":"Zheng J, Gu J, Su Y, et al.. Efficacy of belimumab in patients with systemic lupus erythematosus from North East Asia: Results of exploratory subgroup analyses. Mod Rheumatol. 2023, 33:751-7. 10.1093\/mr\/roac076","journal-title":"Mod Rheumatol"},{"key":"ref213","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajem.2008.11.006","article-title":"Acute inflammatory demyelinating polyneuropathy as the initial presentation of lupus","volume":"27","author":"Hsu TY","year":"2009","unstructured":"Hsu TY, Wang SH, Kuo CF, Chiu TF, Chang YC. Acute inflammatory demyelinating polyneuropathy as the initial presentation of lupus. Am J Emerg Med. 2009, 27:900.e3-5. 10.1016\/j.ajem.2008.11.006","journal-title":"Am J Emerg Med"},{"key":"ref214","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.070367","article-title":"EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics","volume":"67","author":"Bertsias G","year":"2008","unstructured":"Bertsias G, Ioannidis JP, Boletis J, et al.. EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics. Ann Rheum Dis. 2008, 67:195-205. 10.1136\/ard.2007.070367","journal-title":"Ann Rheum Dis"},{"key":"ref215","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2018.03.001","article-title":"Mechanisms of neuropsychiatric lupus: the relative roles of the blood-cerebrospinal fluid barrier versus blood-brain barrier","volume":"91","author":"Gelb S","year":"2018","unstructured":"Gelb S, Stock AD, Anzi S, Putterman C, Ben-Zvi A. Mechanisms of neuropsychiatric lupus: the relative roles of the blood-cerebrospinal fluid barrier versus blood-brain barrier. J Autoimmun. 2018, 91:34-44. 10.1016\/j.jaut.2018.03.001","journal-title":"J Autoimmun"},{"key":"ref216","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2014.04.002","article-title":"Neuropsychiatric systemic lupus erythematosus: tools for the diagnosis","volume":"13","author":"Zardi EM","year":"2014","unstructured":"Zardi EM, Taccone A, Marigliano B, Margiotta DP, Afeltra A. Neuropsychiatric systemic lupus erythematosus: tools for the diagnosis. Autoimmun Rev. 2014, 13:831-9. 10.1016\/j.autrev.2014.04.002","journal-title":"Autoimmun Rev"},{"key":"ref217","doi-asserted-by":"publisher","DOI":"10.6061\/clinics\/2020\/e1515","article-title":"Neuropsychiatric lupus erythematosus: future directions and challenges; a systematic review and survey","volume":"75","author":"Zhang Y","year":"2020","unstructured":"Zhang Y, Han H, Chu L. Neuropsychiatric lupus erythematosus: future directions and challenges; a systematic review and survey. Clinics (Sao Paulo). 2020, 75:1515. 10.6061\/clinics\/2020\/e1515","journal-title":"Clinics (Sao Paulo)"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/341162-neurological-manifestations-of-systemic-lupus-erythematosus-a-comprehensive-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T17:09:44Z","timestamp":1740416984000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/341162-neurological-manifestations-of-systemic-lupus-erythematosus-a-comprehensive-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,24]]},"references-count":217,"URL":"https:\/\/doi.org\/10.7759\/cureus.79569","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2,24]]}}}